CUMULATIVE
SUPPLEMENT 7

JAN'94-JUL'94



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

Cumulative Supplement 7

JULY 1994

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

CUMULATIVE SUPPLEMENT 7

JULY 1994

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 14th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing overstruck print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∂ " symbol to designate their non-marketed status. All products having a " ∂ " symbol in the 12th Cumulative Supplement of the 14th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 15th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ADRIA LABORATORIES DIV ERBAMONT INC (ADRIA)	PHARMACIA INC (PHARMACIA)
BANNER GELATIN PRODUCTS CORP (BANNER GELATIN)	BANNER PHARMACAPS INC (BANNER PHARMACAPS)
CLONMEL CHEMICALS CO LTD (CLONMEL)	CLONMEL HEALTHCARE LIMITED (CLONMEL)
DUPONT PHARMACEUTICALS (DUPONT)	DUPONT MERCK PHARMACEUTICALS CO (DUPONT MERCK)
GYNEX INC (GYNEX)	BTG PHARMACEUTICALS CORP SUB BIOTECHNOLOGY GENERAL CORP (BTG PHARMS)
MALLINCKRODT SPECIALTY CHEMICALS CO (MALLINCKRODT)	MALLINCKRODT CHEMICAL INC (MALLINCKRODT)
NORTH AMERICAN CHEMICAL CORP (NORTH AM CHEM)	GOLDEN PHARMACEUTICALS (GOLDEN PHARM)
PHARMACAPS INC (PHARMACAPS)	BANNER PHARMACAPS INC (BANNER PHARMACAPS)
RICHLYN LABORATORIES INC (RICHLYN)	GLOBAL PHARMACEUTICAL CORPORATION (GLOBAL PHARM)

1.4 NEW INDICATIONS FOR PREVIOUSLY APPROVED DRUG PRODUCTS

When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by the same firm, the application is either sumitted as a supplement to the original NDA (if the clinical expertise for the review of the new indication resides in the same division that reviewed the original NDA), or as a "Type 6 NDA" and assigned a new NDA number (if the clinical expertise for the review of the new indication resides in another review division). When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by a different firm, the application is classified as "Type 6" and assigned a new NDA number.For administrative purposes, FDA has been listing all "Type 6 NDA's" in the *Approved Drug Products with Therapeutic Equivalence Evaluations*, (ADP), even when the application was submitted by the original NDA holder. However, FDA has determined that the practice of listing a separate "Type 6 NDA" number in the ADP when the applicant is the original NDA holder may cause confusion to the ADP reader.

Accordingly, to prevent confusion and to eliminate duplicity of data, the approval of an application for a new indication for a previously approved drug product submitted by the original NDA holder will no longer be listed in the ADP. Any exclusivity awarded for that approval will be shown in the Patent and Exclusivity Information Addendum under the original NDA number. However, approval of an application for a new indication submitted by an applicant other than the original NDA holder will be shown in the appropriate drug product list of the ADP. Any exclusivity awarded will be shown under the NDA number of the new applicant.

All approvals of "Type 6" applications submitted by the original NDA holder currently in the ADP are listed in the table below. For reference purposes, the original NDA number is listed next to the corresponding "Type 6 NDA Number". This data ("Type

6 NDA Number") will continue to be listed in the remaining Cumulative Supplements to the 14th Edition of the ADP; but it will not appear in the 15th Edition of the ADP.

TYPE 6 NDA NUMBER	ORIGINAL NDA NUMBER	ACTIVE INGREDIENT (TRADE NAME)	DOSAGE FORM (ROUTE)
17-117	16-020	AMANTADINE HCL (SYMMETREL)	CAPSULE (ORAL)
17-118	16-023	AMANTADINE HCL (SYMMETREL)	SYRUP (ORAL)
50-697	50-662	CLARITHROMYCIN (BIAXIN)	TABLET (ORAL)
19-576	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
19-648	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
18-064	18-063	NADOLOL (CORGARD)	TABLET (ORAL)
20-109	19-886	NAFARELIN ACETATE (SYNAREL)	SPRAY, METERED (NASAL)
20-223	19-057	TERAZOSIN HCL (HYTRIN)	TABLET (ORAL)

1.5 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF JUNE 1994.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1993) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1993	MAR 1994	JUN 1994	SEP 1994
DRUG PRODUCTS LISTED	9140	9153	9079	
SINGLE SOURCE	2144 (23.5%)	2151 (23.5%)	2150 (23.7%)	
MULTISOURCE	6996 (76.5%)	7002 (76.5%)	6929 (76.3%)	
THERAPEUTICALLY EQUIVALENT	6292 (68.8%)	6306 (68.9%)	6290 (69.3%)	
NOT THERAPEUTICALLY EQUIVALENT	527 (5.8%)	513 (5.6%)	458 (5.0%)	
EXCEPTIONS[1]	177 (1.9%)	183 (2.0%)	181 (2.0%)	
NEW MOLECULAR ENTITIES APPROVED	--	6	5	
NUMBER OF APPLICANTS	526	528	490	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

> DLT >		**/MEDIGESIC PLUS/**			
> DLT >	**/AB/**	/US/CHEM/	**/325MG;50MG;40MG/**	/N89115/001/ /JAN/14,/1986/	
> DLT >					
> ADD >		**MEDIGESIC PLUS**			
> ADD >		@ US CHEM	325MG;50MG;40MG	N89115 001 JAN 14, 1986	
> ADD >					

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE			
AT	BAUSCH AND LOMB	**2%;0.79%**	**N40063 001** FEB 25, 1994	
	/BOROFAIR/			
/AT/	/PHARMAFAIR/	**/2%;0.79%/**	/N88606/001/ /AUG/21,/1985/	[1]
	@ PHARMAFAIR	2%;0.79%	N88606 001 AUG 21, 1985	

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

	SEMPREX-D		
+	BURROUGHS WELLCOME	8MG;60MG	N19806 001 MAR 25, 1994

ALBUTEROL SULFATE

TABLET; ORAL

	ALBUTEROL SULFATE			
> DLT > **/AB/**	/WARNER/CHILCOTT/	**/EQ 2MG BASE/**	/N72817/001/ /JAN/09,/1990/	
> DLT >				
> DLT > **/AB/**		**/EQ 4MG BASE/**	/N72818/001/ /JAN/09,/1990/	
> DLT >				
> ADD >	@ WARNER CHILCOTT	EQ 2MG BASE	N72817 001 JAN 09, 1990	
> ADD >				
> ADD >	@	EQ 4MG BASE	N72818 001 JAN 09, 1990	
> ADD >				

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM			
AB	MYLAN	**0.25MG**	**N74215 001** JAN 27, 1994	
AB		**0.5MG**	**N74215 002** JAN 27, 1994	
AB		**1MG**	**N74215 003** JAN 27, 1994	
AB		**2MG**	**N74215 004** JAN 27, 1994	
AB	NOVOPHARM	**0.25MG**	**N74085 001** FEB 16, 1994	
AB		**0.5MG**	**N74085 002** FEB 16, 1994	
AB		**1MG**	**N74085 003** FEB 16, 1994	
> ADD > **AB**	ZENITH LABS	**0.25MG**	**N74294 001** JUL 29, 1994	
> ADD >				
> ADD > **AB**		**0.5MG**	**N74294 002** JUL 29, 1994	
> ADD >				
> ADD > **AB**		**1MG**	**N74294 003** JUL 29, 1994	
> ADD >				
> ADD > **AB**		**2MG**	**N74294 004** JUL 29, 1994	
> ADD >				

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN			
AP	BEDFORD	**EQ 50MG BASE/ML**	**N63313 001** APR 11, 1994	
AP		**EQ 250MG BASE/ML**	**N63315 001** APR 11, 1994	
/AP/	/ELKINS/SINN/	**/EQ 50MG BASE/ML/**	/N63274/001/ /MAY/18,/1992/	
AP +	ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001** MAY 18, 1992	
/AP/		**/EQ 250MG BASE/ML/**	/N63275/001/ /MAY/18,/1992/	
AP +		**EQ 250MG BASE/ML**	**N63275 001** MAY 18, 1992	

[1] DUE TO PROGRAMMING CHANGES, EACH FIELD ON A PREVIOUSLY DELETED OR CURRENTLY DELETED DRUG PRODUCT LINE HAS BEEN CHANGED TO ONLY SHOW THE OVERSTRUCK SYMBOL BEFORE AND AFTER EACH FIELD RATHER THAN OVER EACH CHARACTER OF THE ENTIRE ENTRY.

AMIKACIN SULFATE

INJECTABLE; INJECTION
/AMIKIN/

/AP//+//BRISTOL/	/EQ 50MG BASE/ML/	/N50495/001/	
/AP/	/EQ 50MG BASE/ML/	/N62562/001/ /SEP/20,/1984/	
/AP//+/	/EQ 250MG BASE/ML/	/N50495/002/	
/AP/	/EQ 250MG BASE/ML/	/N62562/002/ /SEP/20,/1984/	
@ APOTHECON	EQ 50MG BASE/ML	N50495 001	
@	EQ 250MG BASE/ML	N50495 002	
@ BRISTOL	EQ 50MG BASE/ML	N62562 001 SEP 20, 1984	
@	EQ 250MG BASE/ML	N62562 002 SEP 20, 1984	

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

/ABBOTT/	/5%;25GM/100ML/	/N19565/001/ /DEC/17,/1986/
@ ABBOTT	5%;25GM/100ML	N19565 001 DEC 17, 1986

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

/AP/ /FUJISAWA/	/25MG/ML/	/N87886/001/ /AUG/30,/1983/	
@ FUJISAWA	25MG/ML	N87886 001 AUG 30, 1983	
>ADD> AP KING PHARMS	25MG/ML	N86606 001	
>DLT>/AP/ /SMITHKLINE/BEECHAM/	/25MG/ML/	/N86606/001/	

TABLET; ORAL
AMINOPHYLLINE

/BD/ /LANNETT/	/100MG/	/N84588/001/	
/BD/	/200MG/	/N84588/002/	
@ LANNETT	100MG	N84588 001	
@	200MG	N84588 002	
AB RICHLYN	100MG	N84574 001	
AB	200MG	N84576 001	
/BD/	/100MG/	/N84574/001/	
/BD/	/200MG/	/N84576/001/	

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL
PASER

+ JACOBUS	4GM/PACKET	N74346 001 JUN 30, 1994

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

>DLT>/AB/ /LEMMON/	/10MG/	/N86610/001/	
>DLT>/AB/	/25MG/	/N86859/001/	
>DLT>/AB/	/50MG/	/N86857/001/	
>DLT>/AB/	/75MG/	/N86860/001/	
>DLT>/AB/	/100MG/	/N86854/001/	
>DLT>/AB/	/150MG/	/N86853/001/	
>ADD> @ LEMMON	10MG	N86610 001	
>ADD> @	25MG	N86859 001	
>ADD> @	50MG	N86857 001	
>ADD> @	75MG	N86860 001	
>ADD> @	100MG	N86854 001	
>ADD> @	150MG	N86853 001	

AMOXICILLIN

CAPSULE; ORAL
POLYMOX

AB APOTHECON	250MG	N63099 001 MAR 20, 1992	
AB	500MG	N63099 002 MAR 20, 1992	
/AB/ /BRISTOL/MYERS/	/250MG/	/N63099/001/ /MAR/20,/1992/	
/AB/	/500MG/	/N63099/002/ /MAR/20,/1992/	

POWDER FOR RECONSTITUTION; ORAL
/POLYMOX/

/AB/ /BRISTOL/	/125MG/5ML/	/N61851/001/	
/AB/	/125MG/5ML/	/N62323/001/	
/AB/	/250MG/5ML/	/N61851/002/	
/AB/	/250MG/5ML/	/N62323/002/	
@ APOTHECON	125MG/5ML	N61851 001	
@	125MG/5ML	N62323 001	
@	250MG/5ML	N61851 002	
@	250MG/5ML	N62323 002	

AMPHETAMINE SULFATE

/TABLET;/ORAL/
/AMPHETAMINE/SULFATE/

/LANNETT/	/5MG/	/N83901/001/	
		/AUG/31,/1984/	
	/10MG/	/N83901/002/	
		/AUG/31,/1984/	
@ LANNETT	5MG	N83901 001	
		AUG 31, 1984	
@	10MG	N83901 002	
		AUG 31, 1984	

AMPHOTERICIN B

INJECTABLE; INJECTION
AMPHOTERICIN B

/AP/ /FUJISAWA/	/50MG/VIAL/	/N62728/001/	
		/APR/13,/1987/	
@ FUJISAWA	50MG/VIAL	N62728 001	
		APR 13, 1987	

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL
POLYCILLIN

@ APOTHECON	EQ 125MG BASE/5ML	N62297 001	
@	EQ 250MG BASE/5ML	N62297 002	
/AB/ /BRISTOL/	/EQ 125MG BASE/5ML/	/N62297/001/	
/AB/	/EQ 250MG BASE/5ML/	/N62297/002/	

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
/M.V.C. 9+3/

/AP/ /FUJISAWA/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/		
	/1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/		
	/0.4MG/ML;0.36MG/ML;0.3MG/ML;/		
	/330 UNITS/ML;1 IU/ML/	/N18440/002/	
		/AUG/08,/1985/	
@ FUJISAWA	10MG/ML;0.006MG/ML;0.5UGM/ML;		
	1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;		
	0.4MG/ML;0.36MG/ML;0.3MG/ML;		
	330 UNITS/ML;1 IU/ML	N18440 002	
		AUG 08, 1985	

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	GENPHARM	50MG	**N74126 001**
			MAR 23, 1994
AB		100MG	**N74126 002**
			MAR 23, 1994
AB	INVAMED	25MG	**N74265 001**
			FEB 28, 1994
AB		50MG	**N74265 002**
			FEB 28, 1994
AB		100MG	**N74265 003**
			FEB 28, 1994

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
/LOFENE/

/AA/ /LANNETT/	/0.025MG;2.5MG/	/N85372/001/	
@ LANNETT	0.025MG;2.5MG	N85372 001	

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN

>DLT >/AT/ /PHARMADERM/	/500 UNITS/GM/	/N62158/001/	
>ADD > @ PHARMADERM	500 UNITS/GM	N62158 001	
/AT/ /PHARMAFAIR/	/500 UNITS/GM/	/N62453/001/	
		/MAR/28,/1984/	
@ PHARMAFAIR	500 UNITS/GM	N62453 001	
		MAR 28, 1984	

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	ROYCE	10MG	**N73092 001**
			JAN 28, 1994
AB		20MG	**N73093 001**
			JAN 28, 1994

BENZYL BENZOATE

/EMULSION;/TOPICAL/
/BENZYL/BENZOATE/

/+//LANNETT/	/50%/	/N84535/001/	
@ LANNETT	50%	N84535 001	

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL
/DIPROLENE/
/+//SCHERING/ /EQ/0.05%/BASE/ /N19408/001/
/JAN/31,/1986/
@ SCHERING EQ 0.05% BASE N19408 001
JAN 31, 1986

GEL; TOPICAL
DIPROLENE
+ SCHERING EQ 0.05% BASE N19408 002
NOV 22, 1991

BETAMETHASONE VALERATE

OINTMENT; TOPICAL
BETAMETHASONE VALERATE
/B*/ /CLAY/PARK/ /EQ/0.1%/BASE/ /N71478/001/
/DEC/23,/1987/
@ CLAY PARK EQ 0.1% BASE N71478 001
DEC 23, 1987

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE
/**AA**/ /LANNETT/ /**5MG**/ /N84702/001/
/**AA**/ /**10MG**/ /N84712/001/
/**AA**/ /**25MG**/ /N84074/001/
@ LANNETT 5MG N84702 001
@ 10MG N84712 001
@ 25MG N84074 001

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
DIMETANE-DX
>DLT >/**AA**/ /ROBINS/AH/ /**2MG/5ML**;**10MG/5ML**;/
>DLT > /**30MG/5ML**/ /N11694/007/
>DLT > /MAR/29,/1984/

BUDESONIDE

AEROSOL, METERED; NASAL
RHINOCORT
+ ASTRA 0.05MG/INH N20233 001
FEB 14, 1994

BUTABARBITAL SODIUM

ELIXIR; ORAL
/BUTALAN/
/LANNETT/ /33.3MG/5ML/ /N85880/001/
@ LANNETT 33.3MG/5ML N85880 001

TABLET; ORAL
BUTISOL SODIUM
/**AA**/ /WALLACE/ /**100MG**/ /N00793/005/
WALLACE 100MG N00793 005
SODIUM BUTABARBITAL
/**AA**/ /LANNETT/ /**100MG**/ /N85881/001/
@ LANNETT 100MG N85881 001
/**AA**/ /ZENITH/ /**30MG**/ /N84040/001/
@ ZENITH 30MG N84040 001

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT
BR G AND W LABS 100MG;2MG N86557 001
OCT 04, 1983
/WIGRAINE/
/BR/ /ORGANON/ /100MG;2MG/ /N86557/001/
/OCT/04,/1983/

CALCIFEDIOL

CAPSULE; ORAL
CALDEROL
+ ORGANON 0.05MG N18312 002
0.02MG N18312 001

CALCIFEDIOL, ANHYDROUS

/CAPSULE;/ORAL/
/CALDEROL/
/+//ORGANON/ /0.05MG/ /N18312/002/
/0.02MG/ /N18312/001/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS — **18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20171 001** AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS — **18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20171 002** AUG 19, 1992

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS — **18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20171 003** AUG 19, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER — **18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20183 001** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER — **18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20183 002** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER — **18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20183 003** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER — **18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20183 004** DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER — **18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N17512 004**

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT ABBOTT — **18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20374 001** JUN 13, 1994

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT ABBOTT — **18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20374 002** JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT ABBOTT — **18.4MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20374 003** JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT ABBOTT — **18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** — **N20374 004** JUN 13, 1994

CARBACHOL

/INJECTABLE;/INJECTION/

/CARBACHOL/

/@/PHARMAFAIR/ — /0.01%/ — /N70292/001/ /MAY/21,/1986/

/MIOSTAT/

/+//ALCON/ — /0.01%/ — /N16968/001/

SOLUTION; INTRAOCULAR

CARBACHOL

@ PHARMAFAIR — 0.01% — N70292 001 MAY 21, 1986

MIOSTAT

\+ ALCON — 0.01% — N16968 001

CARBAMAZEPINE

SUSPENSION; ORAL

TEGRETOL

\+ BASEL PHARMS — 100MG/5ML — N18927 001 DEC 18, 1987

/+//GEIGY/ — /100MG/5ML/ — /N18927/001/ /DEC/18,/1987/

TABLET; ORAL

TEGRETOL

AB + BASEL PHARMS — **200MG** — **N16608 001**

/AB//+//GEIGY/ — **/200MG/** — /N16608/001/

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL
TEGRETOL

AB	+ BASEL PHARMS	100MG	N18281 001
/AB/	/+/GEIGY/	/100MG/	/N18281/001/

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

AB	SCS	10MG;100MG	N74080 001 MAR 25, 1994
AB		25MG;100MG	N74080 002 MAR 25, 1994
AB		25MG;250MG	N74080 003 MAR 25, 1994

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

	/@/ZENITH/	/EQ/500MG/BASE/	/N62766/001/ /MAR/03,/1987/
>ADD> AB	APOTHECON	EQ 500MG BASE	N62291 001
AB	ZENITH	EQ 500MG BASE	N62766 001 MAR 03, 1987
>DLT>	/ULTRACEF/		
>DLT>/AB/	/BRISTOL/	/EQ 500MG BASE/	/N62291/001/

POWDER FOR RECONSTITUTION; ORAL
CEFADROXIL

AB	APOTHECON	EQ 125MG BASE/5ML	N62334 001
AB		EQ 250MG BASE/5ML	N62334 002
AB		EQ 500MG BASE/5ML	N62334 003
	/ULTRACEF/		
/AB/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N62334/001/
/AB/		/EQ 250MG BASE/5ML/	/N62334/002/
/AB/		/EQ 500MG BASE/5ML/	/N62334/003/

TABLET; ORAL
CEFADROXIL

	/@/ZENITH/	/EQ/1GM/BASE/	/N62774/001/
AB	ZENITH	EQ 1GM BASE	N62774 001 APR 08, 1987

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET; ORAL
ULTRACEF

AB	APOTHECON	EQ 1GM BASE	N62390 001 JUN 10, 1982
/AB/	/BRISTOL/	/EQ 1GM BASE/	/N62390/001/ /JUN/10,/1982/

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

/AP/	/FUJISAWA/	/EQ 500MG BASE/VIAL/	/N62688/002/ /NOV/17,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N62688/003/ /NOV/17,/1986/
/AP/		/EQ 10GM BASE/VIAL/	/N62688/004/ /NOV/17,/1986/
/AP/		/EQ 20GM BASE/VIAL/	/N62688/005/ /AUG/03,/1987/
	@ FUJISAWA	EQ 500MG BASE/VIAL	N62688 002 NOV 17, 1986
	@	EQ 1GM BASE/VIAL	N62688 003 NOV 17, 1986
	@	EQ 10GM BASE/VIAL	N62688 004 NOV 17, 1986
	@	EQ 20GM BASE/VIAL	N62688 005 AUG 03, 1987

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

FUJISAWA	EQ 1GM BASE/VIAL	N63294 002 MAR 31, 1994
	EQ 2GM BASE/VIAL	N63294 003 MAR 31, 1994

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL
CEFTIN

+ GLAXO	EQ 125MG BASE/5ML	N50672 001 JUN 30, 1994

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

	/SEFFIN/			
/AP/	/GLAXO/	/EQ 1GM BASE/VIAL/	/N62435/001/ /NOV/15,/1983/	
/AP/		/EQ 2GM BASE/VIAL/	/N62435/002/ /NOV/15,/1983/	
/+/		/EQ/10GM/BASE/VIAL/	/N62435/003/ /NOV/15,/1983/	
	@ GLAXO	EQ 1GM BASE/VIAL	N62435 001 NOV 15, 1983	
	@	EQ 2GM BASE/VIAL	N62435 002 NOV 15, 1983	
	@	EQ 10GM BASE/VIAL	N62435 003 NOV 15, 1983	

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC

	/CHLOROFAIR/			
/AT/	/PHARMAFAIR/	/1%/	/N62439/001/ /APR/21,/1983/	
	@ PHARMAFAIR	1%	N62439 001 APR 21, 1983	

SOLUTION/DROPS; OPHTHALMIC

	/CHLOROFAIR/			
/AT/	/PHARMAFAIR/	/0.5%/	/N62437/001/ /APR/14,/1983/	
	@ PHARMAFAIR	0.5%	N62437 001 APR 14, 1983	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

	PERIDEX			
AT	+ PROCTER AND GAMBLE	0.12%	N19028 001 AUG 13, 1986	
	PERIOGARD			
AT	COLGATE PALMOLIVE	0.12%	N73695 001 JAN 14, 1994	

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

	CHLORPHENIRAMINE MALEATE			
/AA/	/ZENITH/	/4MG/	/N80779/001/	
	@ ZENITH	4MG	N80779 001	

CHLORTHALIDONE

TABLET; ORAL

	THALITONE			
+	HORUS THERAP	15MG	N19574 001 DEC 20, 1988	
		/15MG/	/N19574/001/ /DEC/20,/1988/	

CHOLESTYRAMINE

TABLET; ORAL

	QUESTRAN		
+	BRISTOL MYERS SQUIBB	EQ 1GM RESIN	N73403 001 APR 28, 1994

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
AB	ENDO LABS	200MG	N74281 001 MAY 17, 1994	
AB		300MG	N74281 002 MAY 17, 1994	
AB		400MG	N74281 003 MAY 17, 1994	
AB		800MG	N74329 001 MAY 17, 1994	
AB	MYLAN	200MG	N74246 001 MAY 17, 1994	
AB		300MG	N74246 002 MAY 17, 1994	
AB		400MG	N74246 003 MAY 17, 1994	
AB		800MG	N74246 004 MAY 17, 1994	
AB	NOVOPHARM	200MG	N74151 001 MAY 17, 1994	
AB		300MG	N74151 002 MAY 17, 1994	
AB		400MG	N74151 003 MAY 17, 1994	
AB		800MG	N74463 001 MAY 17, 1994	
	TAGAMET			
AB	SMITHKLINE BEECHAM	200MG	N17920 002	
AB		300MG	N17920 003	
AB		400MG	N17920 004 DEC 14, 1983	
AB	+	800MG	N17920 005 APR 30, 1986	

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

	CIMETIDINE HCL			
AA	BARRE	**EQ 300MG BASE/5ML**	**N74176 001**	JUN 01, 1994
	TAGAMET			
AA	SMITHKLINE BEECHAM	**EQ 300MG BASE/5ML**	**N17924 001**	

CLEMASTINE FUMARATE

SYRUP; ORAL

	CLEMASTINE FUMARATE			
AA	LEMMON	**EQ 0.5MG BASE/5ML**	**N73399 001**	JUN 30, 1994

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE			
AP	BEDFORD	**EQ 150MG BASE/ML**	**N63163 001**	JUN 30, 1994
/AP/	/DUPONT/	**/EQ 150MG BASE/ML/**	/N62908/001/	/FEB/01,/1989/
	@ DUPONT MERCK	EQ 150MG BASE/ML	N62908 001	FEB 01, 1989
/AP/	/FUJISAWA/	**/EQ 150MG BASE/ML/**	/N62747/001/	/JUN/03,/1988/
	@ FUJISAWA	EQ 150MG BASE/ML	N62747 001	JUN 03, 1988

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	CLOBETASOL PROPIONATE			
AB	COPLEY	**0.05%**	**N74087 001**	FEB 16, 1994
	TEMOVATE			
AB	+ GLAXO	**0.05%**	**N19322 001**	DEC 27, 1985
AB	+	**0.05%**	**N20340 001**	JUN 17, 1994

GEL; TOPICAL

	TEMOVATE		
+	GLAXO	0.05%	N20337 001 APR 29, 1994

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

	CLOBETASOL PROPIONATE			
AB	COPLEY	**0.05%**	**N74089 001**	FEB 16, 1994
	TEMOVATE			
AB	+ GLAXO	**0.05%**	**N19323 001**	DEC 27, 1985

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	ANAFRANIL			
+	BASEL PHARMS	75MG	N19906 003	DEC 29, 1989
		25MG	N19906 001	DEC 29, 1989
		50MG	N19906 002	DEC 29, 1989
	/+//CIBA/	/75MG/	/N19906/003/	/DEC/29,/1989/
		/25MG/	/N19906/001/	/DEC/29,/1989/
		/50MG/	/N19906/002/	/DEC/29,/1989/

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETHAZINE VC W/ CODEINE			
AA	PENNEX	**10MG/5ML;5MG/5ML; 6.25MG/5ML**	**N88896 001**	JAN 04, 1985
	/@/	/10MG/5ML;5MG/5ML;/ /6.25MG/5ML/	/N88896/001/	/JAN/04,/1985/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETHAZINE W/ CODEINE			
AA	PENNEX	**10MG/5ML;6.25MG/5ML**	**N88875 001**	DEC 17, 1984
	/@/	/10MG/5ML;6.25MG/5ML/	/N88875/001/	/DEC/17,/1984/

COLESTIPOL HYDROCHLORIDE

>_ADD_>	TABLET; ORAL			
>_ADD_>	COLESTID			
>_ADD_>	UPJOHN	1GM	N20222 001	
>_ADD_>			JUL 19, 1994	

CORTISONE ACETATE

	INJECTABLE; INJECTION		
	/CORTISONE/ACETATE/		
/BP/	/STERIS/	/25MG/ML/	/N85677/001/
/BP/		/50MG/ML/	/N85677/002/
/BP/		/25MG/ML/	/N83147/003/
/BP/		/50MG/ML/	/N83147/004/
/BP/	/UPJOHN/	/25MG/ML/	/N08126/002/
	@ STERIS	25MG/ML	N83147 003
	@	25MG/ML	N85677 001
	@	50MG/ML	N83147 004
	@	50MG/ML	N85677 002
	@ UPJOHN	25MG/ML	N08126 002
	CORTONE		
/BP/	/MSD/	/25MG/ML/	/N07110/002/
/BP/+/		/50MG/ML/	/N07110/003/
	+ MSD	50MG/ML	N07110 003
		25MG/ML	N07110 002

CROMOLYN SODIUM

	SOLUTION; INHALATION			
	CROMOLYN SODIUM			
AN	DEY	**10MG/ML**	**N74209 001**	
			APR 26, 1994	
	INTAL			
AN	+ FISONS	**10MG/ML**	**N18596 001**	
			MAY 28, 1982	

CYCLOPENTOLATE HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC			
	PENTOLAIR			
AT	BAUSCH AND LOMB	**1%**	**N40075 001**	
			APR 29, 1994	

CYPROHEPTADINE HYDROCHLORIDE

	TABLET; ORAL			
	CYPROHEPTADINE HCL			
/**AA**/	/CHELSEA/LABS/	/**4MG**/	/N86165/001/	
	@ CHELSEA LABS	4MG	N86165 001	

CYTARABINE

	INJECTABLE; INJECTION		
	CYTARABINE		
	+ BULL	20MG/ML	N72945 001
			FEB 28, 1994

DACTINOMYCIN

	INJECTABLE; INJECTION		
	COSMEGEN		
	+ MERCK SHARP DOHME	0.5MG/VIAL	N50682 001
	/+//MSD/	/0.5MG/VIAL/	/N60467/001/

DESMOPRESSIN ACETATE

	SPRAY, METERED; NASAL		
	DESMOPRESSIN ACETATE		
	+ RHONE POULENC RORER	0.15MG/INH	N20355 001
			MAR 07, 1994

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

	OINTMENT; OPHTHALMIC			
>_ADD_>	**DEXASPORIN**			
>_ADD_> **AT**	BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE;**		
>_ADD_>		**10,000 UNITS**	**N64063 001**	
>_ADD_>			JUL 25, 1994	

DEXAMETHASONE SODIUM PHOSPHATE

	AEROSOL; NASAL			
>_DLT_>	/DECADRON/			
>_DLT_>	/+//MSD/	/EQ/0.1MG/PHOSPHATE/INH/	/N14242/001/	
>_ADD_>	DEXACORT			
>_ADD_>	+ MEDEVA	EQ 0.1MG PHOSPHATE/INH	N14242 001	
	AEROSOL, METERED; INHALATION			
>_DLT_>	/DECADRON/			
>_DLT_>	/+//MSD/	/EQ/0.1MG/PHOSPHATE/INH/	/N13413/001/	

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL, METERED; INHALATION

>_ADD_>	DEXACORT			
>_ADD_>	+ MEDEVA	EQ 0.1MG PHOSPHATE/INH	N13413	001

DEXTROAMPHETAMINE SULFATE

/ELIXIR;/ORAL/
/DEXEDRINE/

/SMITHKLINE/BEECHAM/	/5MG/5ML/	/N83902/001/	
@ SMITHKLINE BEECHAM	5MG/5ML	N83902	001

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

/AA/	/LANNETT/	/5MG/	/N83903/001/	
/AA/		/10MG/	/N83903/003/	
@ LANNETT		5MG	N83903	001
@		10MG	N83903	003
		/15MG/	/N85652/001/	
@		15MG	N85652	001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE W/ DEXTROMETHORPHAN

AA	PENNEX	15MG/5ML;6.25MG/5ML	N88864	001
			JAN 04, 1985	
/@/		/15MG/5ML;6.25MG/5ML/	/N88864/001/	
			/JAN/04,/1985/	

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	50MG/ML	N16730	002

DEXTROTHYROXINE SODIUM

TABLET; ORAL
CHOLOXIN

+ BOOTS	4MG	N12302	004
/+/	/6MG/	/N12302/006/	
	/4MG/	/N12302/004/	
@	6MG	N12302	006

DIENESTROL

CREAM; VAGINAL
/ESTRAGUARD/

/AT/ /SOLVAY/	/0.01%/	/N84436/001/	
@ SOLVAY	0.01%	N84436	001

DIETHYLSTILBESTROL

TABLET; ORAL
DIETHYLSTILBESTROL

/BP/ /LILLY/	/1MG/	/N04041/004/	
/BP/+/	/5MG/	/N04041/005/	
+ LILLY	5MG	N04041	005
	1MG	N04041	004

STILBESTROL

/BP/ /TABLICAPS/	/1MG/	/N83002/001/	
/BP/	/5MG/	/N83006/001/	
@ TABLICAPS	1MG	N83002	001
@	5MG	N83006	001

TABLET, DELAYED RELEASE; ORAL
/STILBESTROL/

/BE/ /TABLICAPS/	/0.5MG/	/N83003/001/	
/BE/	/1MG/	/N83005/001/	
/BE/	/5MG/	/N83007/001/	
@ TABLICAPS	0.5MG	N83003	001
@	1MG	N83005	001
@	5MG	N83007	001

/STILBETIN/

/BE/ /SQUIBB/	/0.5MG/	/N04056/012/	
/BE/	/1MG/	/N04056/013/	
/BE/	/5MG/	/N04056/014/	
@ SQUIBB	0.5MG	N04056	012
@	1MG	N04056	013
@	5MG	N04056	014

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

AB	NOVOPHARM	30MG	N74084	001
			FEB 25, 1994	
AB		60MG	N74084	002
			FEB 25, 1994	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

/AA/	/LANNETT/	/25MG/	/N80868/001/
/AA/		/50MG/	/N80868/002/
	@ LANNETT	25MG	N80868 001
	@	50MG	N80868 002

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DIPIVEFRIN HCL

AT	ALCON	0.1%	N73636 001 JUN 30, 1994

PROPINE

AT	+ ALLERGAN	0.1%	N18239 001

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

>ADD>	AP	ABBOTT	EQ 400MG BASE/100ML	N20201 006 JUL 07, 1994
>ADD>				
>ADD>	AP	+ BAXTER	EQ 400MG BASE/100ML	N20255 005 OCT 19, 1993
>ADD>				

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON

	+ GENDERM	5%	N20126 001 APR 01, 1994

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ADRIAMYCIN PFS

/AP//+//ADRIA/		/200MG/100ML/	/N50629/002/ /MAY/03,/1988/
/AP/		/200MG/100ML/	/N63165/002/ /JAN/30,/1991/
	+ ADRIA	200MG/100ML	N50629 002 MAY 03, 1988
		200MG/100ML	N63165 002 JAN 30, 1991

ENFLURANE

LIQUID; INHALATION
ENFLURANE

>ADD>	AN	INHALON	99.9%	N74396 001 JUL 29, 1994
>ADD>				

ERGOCALCIFEROL

CAPSULE; ORAL
/DELTALIN/

/AA/	/LILLY/	/50,000 IU/	/N80884/001/
	@ LILLY	50,000 IU	N80884 001

VITAMIN D

/AA/	/LANNETT/	/50,000 IU/	/N80825/001/
	@ LANNETT	50,000 IU	N80825 001
/AA/	/WEST/WARD/	/50,000 IU/	/N83102/001/
	@ WEST WARD PHARM	50,000 IU	N83102 001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

/AB/	/PARKE/DAVIS/	/250MG/	/N62546/001/ /JUL/25,/1985/
	@ PARKE DAVIS	250MG	N62546 001 JUL 25, 1985

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

>ADD>	AT	BAUSCH AND LOMB	0.5%	N64067 001 JUL 29, 1994
>ADD>				
>DLT>/AT/		/FOUGERA/	/5MG/GM/	/N62447/001/ /SEP/26,/1983/
>DLT>				
>ADD>	AT	FOUGERA	0.5%	N62447 001 SEP 26, 1983
>ADD>				

ILOTYCIN

>DLT>/AT//+//DISTA/			/5MG/GM/	/N50368/001/
>ADD>	AT	+ DISTA	0.5%	N50368 001

SOLUTION; TOPICAL
ERYTHROMYCIN

/AT/	/BARRE/	/2%/	/N62957/001/ /JUL/21,/1988/
	@ BARRE	2%	N62957 001 JUL 21, 1988
AT	BAUSCH AND LOMB	2%	N64039 001 JAN 27, 1994

ERYTHROMYCIN

SOLUTION; TOPICAL

	ERYTHROMYCIN			
/AI/	/PHARMAFAIR/	/2%/	/N62616/001/	
			/JUL/25,/1985/	
	@ PHARMAFAIR	2%	N62616 001	
			JUL 25, 1985	

TABLET, COATED PARTICLES; ORAL

	PCE			
>ADD<	+ ABBOTT	333MG	N50611 001	
>ADD<			SEP 09, 1986	
>DLT<		/333MG/	/N50611/001/	
>DLT<			/SEP/09,/1986/	

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

	ERYTHROMYCIN ETHYLSUCCINATE			
/AB/	/DISTA/	/EQ 200MG BASE/5ML/	/N62177/001/	
/AB/		/EQ 400MG BASE/5ML/	/N62177/002/	
	@ DISTA	EQ 200MG BASE/5ML	N62177 001	
	@	EQ 400MG BASE/5ML	N62177 002	
/AB/	/PHARMAFAIR/	/EQ 200MG BASE/5ML/	/N62559/001/	
			/MAR/15,/1985/	
	@ PHARMAFAIR	EQ 200MG BASE/5ML	N62559 001	
			MAR 15, 1985	

TABLET; ORAL

	E.E.S. 400			
/AB//+/	/ABBOTT/	/EQ 400MG BASE/	/N61905/001/	
/AB/		/EQ 400MG BASE/	/N61905/002/	
			/AUG/12,/1982/	
AB	+ ABBOTT	EQ 400MG BASE	N61905 002	
			AUG 12, 1982	
	@	EQ 400MG BASE	N61905 001	

ERYTHROMYCIN STEARATE

TABLET; ORAL

	/ERYPAR/			
/AB/	/PARKE/DAVIS/	/EQ 250MG BASE/	/N62322/001/	
	ERYPAR			
	@ WARNER CHILCOTT	EQ 250MG BASE	N62322 001	
	ERYTHROMYCIN STEARATE			
/AB/	/PUREPAC/	/EQ 250MG BASE/	/N61743/001/	
	@ PUREPAC PHARM	EQ 250MG BASE	N61743 001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

	/DELADUMONE/			
/AO//+/	/SQUIBB/	/4MG/ML;90MG/ML/	/N09545/001/	
	@ SQUIBB	4MG/ML;90MG/ML	N09545 001	
	TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE			
/AO/	/STERIS/	/4MG/ML;90MG/ML/	/N85865/001/	
	+ STERIS	4MG/ML;90MG/ML	N85865 001	

ESTROGENS, ESTERIFIED

TABLET; ORAL

	ESTRATAB			
/BS/	/SOLVAY/	/0.625MG/	/N83209/001/	
BS +	SOLVAY	0.625MG	N83209 001	
/BS/		/2.5MG/	/N83857/001/	
BS +		2.5MG	N83857 001	
	MENEST			
/BS/+/	/SMITHKLINE/BEECHAM/	/0.625MG/	/N84948/001/	
BS	SMITHKLINE BEECHAM	0.625MG	N84948 001	
/BS/+/		/2.5MG/	/N84949/001/	
BS		2.5MG	N84949 001	

ESTRONE

INJECTABLE; INJECTION

	ESTRONE			
/BP/	/STERIS/	/2MG/ML/	/N83397/001/	
	@ STERIS	2MG/ML	N83397 001	

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

	MYAMBUTOL			
	+ LEDERLE	400MG	N16320 003	
/+/		/500MG/	/N16320/004/	
		/200MG/	/N16320/002/	
	@	200MG	N16320 002	
		/400MG/	/N16320/003/	
	@	500MG	N16320 004	

ETHINAMATE

/CAPSULE;/ORAL/

	/VALMID/			
	/DISTA/	/500MG/	/N09750/001/	
	@ DISTA	500MG	N09750 001	

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

/TABLET;/ORAL-28/
/NORQUEST/FE/

/+//SYNTEX/	/0.035MG;75MG;1MG/	/N18926/001/ /JUL/18,/1986/
@ SYNTEX	0.035MG;75MG;1MG	N18926 001 JUL 18, 1986

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

> DLT >	/WATSON/	/0.035MG;0.5MG/AND/1MG/	/N71041/001/ /SEP/24,/1991/
> ADD > AB	WATSON LABS	0.035MG;0.5MG AND 1MG	N71041 001 SEP 24, 1991
> DLT >	/@/	/0.035MG;0.5MG/AND/1MG/	/N19004/001/ /APR/04,/1984/

ORTHO-NOVUM 7/14-21

> ADD > AB +	JOHNSON RW	0.035MG;0.5MG AND 1MG	N19004 001 APR 04, 1984

TABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

> DLT >	/WATSON/	/0.035MG;0.5MG/AND/1MG/	/N71042/001/ /SEP/24,/1991/
> ADD > AB	WATSON LABS	0.035MG;0.5MG AND 1MG	N71042 001 SEP 24, 1991
> DLT >	/@/	/0.035MG;0.5MG/AND/1MG/	/N19004/002/ /APR/04,/1984/

ORTHO-NOVUM 7/14-28

> ADD > AB +	JOHNSON RW	0.035MG;0.5MG AND 1MG	N19004 002 APR 04, 1984

ETODOLAC

TABLET; ORAL
LODINE

+ WYETH AYERST	400MG	N18922 004 JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	GENSIA	20MG/ML	N74284 001 FEB 10, 1994

ETOPOSIDE

INJECTABLE; INJECTION
VEPESID

AP +	BRISTOL	20MG/ML	N18768 001 NOV 10, 1983

FAMCICLOVIR

TABLET; ORAL
FAMVIR

+ SMITHKLINE BEECHAM	500MG	N20363 002 JUN 29, 1994

FAMOTIDINE

INJECTABLE; INJECTION
PEPCID IN PLASTIC CONTAINER

+ MERCK	0.4MG/ML	N20249 001 FEB 18, 1994

FLUCONAZOLE

TABLET; ORAL
DIFLUCAN

/+//PFIZER/	/50MG/	/N19949/001/ /JAN/29,/1990/
/+/	/100MG/	/N19949/002/ /JAN/29,/1990/
PFIZER	50MG	N19949 001 JAN 29, 1990
	100MG	N19949 002 JAN 29, 1990
	150MG	N20322 001 JUN 30, 1994

FLUMAZENIL

INJECTABLE; INJECTION
/MAZICON/

/+//ROCHE/	/0.1MG/ML/	/N20073/001/ /DEC/20,/1991/
ROMAZICON		
+ ROCHE	0.1MG/ML	N20073 001 DEC 20, 1991

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE

/AT/	/PHARMAFAIR/	/0.01%/	/N88449/001/
			/FEB/08,/1984/
	@ PHARMAFAIR	0.01%	N88449 001
			FEB 08, 1984

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

/B*/	/CLAY/PARK/	/0.05%/	/N71790/001/
			/JUL/13,/1988/
	@ CLAY PARK	0.05%	N71790 001
			JUL 13, 1988

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL

/AP//+//ADRIA/		/50MG/ML/	/N17959/001/
/AP/		/50MG/ML/	/N40023/001/
			/OCT/18,/1991/
AP	+ PHARMACIA	50MG/ML	**N40023 001**
			OCT 18, 1991
	@	50MG/ML	N17959 001

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP

	/+//DISTA/	/0.025%/	/N12806/003/
	/+/	/0.05%/	/N12806/002/
	+ LILLY	0.025%	N12806 003
	+	0.05%	N12806 002

LOTION; TOPICAL
CORDRAN

/AT//+//DISTA/		/0.05%/	/N13790/001/
AT	+ LILLY	0.05%	**N13790 001**

OINTMENT; TOPICAL
CORDRAN

	/+//DISTA/	/0.025%/	/N12806/004/
	/+/	/0.05%/	/N12806/001/

FLURANDRENOLIDE

OINTMENT; TOPICAL
CORDRAN

	+ LILLY	0.025%	N12806 004
	+	0.05%	N12806 001

TAPE; TOPICAL
CORDRAN

	/+//DISTA/	/0.004MG/SQ/CM/	/N16455/001/
	+ LILLY	0.004MG/SQ CM	N16455 001

FLURBIPROFEN

TABLET; ORAL
ANSAID

AB	UPJOHN	50MG	**N18766 002**
			OCT 31, 1988
AB	+	100MG	**N18766 003**
			OCT 31, 1988

FLURBIPROFEN

AB	MYLAN	50MG	**N74358 001**
			JUN 20, 1994
AB		100MG	**N74358 002**
			JUN 20, 1994

FOLIC ACID

TABLET; ORAL
FOLIC ACID

/AA/	/LANNETT/	/1MG/	/N80816/001/
	@ LANNETT	1MG	N80816 001
/AA/	/PUREPAC/	/1MG/	/N80784/001/
	@ PUREPAC	1MG	N80784 001

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP	MARSAM	10MG/ML	**N74017 001**
			JUN 30, 1994
/AP/	/ORGANON/	/10MG/ML/	/N70017/001/
			/DEC/15,/1986/
	@ ORGANON	10MG/ML	N70017 001
			DEC 15, 1986
>_DLT_>/AP/	/WARNER/CHILCOTT/	/10MG/ML/	/N18420/001/
>_DLT_>			/FEB/26,/1982/
>_ADD_>	@ WARNER CHILCOTT	10MG/ML	N18420 001
>_ADD_>			FEB 26, 1982

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

BS	DUPONT	2MCI/ML	N17478 001
/BS/	/DUPONT/MERCK/	/2MCI/ML/	/N17478/001/

GENTAMICIN SULFATE

CREAM; TOPICAL
GARAMYCIN

/AT//+/	/SCHERING/	/EQ 1MG BASE/GM/	/N60462/001/
AT +	SCHERING	EQ 0.1% BASE	N60462 001

GENTAFAIR

/AT/	/PHARMAFAIR/	/EQ 0.1% BASE/	/N62458/001/ /SEP/01,/1983/
	@ PHARMAFAIR	EQ 0.1% BASE	N62458 001 SEP 01, 1983

GENTAMICIN

/AT/	/CLAY/PARK/	/EQ 1MG BASE/GM/	/N62307/001/
AT	CLAY PARK	EQ 0.1% BASE	N62307 001

GENTAMICIN SULFATE

AT	BAUSCH AND LOMB	EQ 0.1% BASE	N64056 001 APR 29, 1994
/AT/	/FOUGERA/	/EQ 1MG BASE/GM/	/N62531/001/ /JUL/05,/1984/
AT	FOUGERA	EQ 0.1% BASE	N62531 001 JUL 05, 1984
/AT/	/NMC/	/EQ 1MG BASE/GM/	/N62471/001/ /SEP/27,/1983/
AT	NMC	EQ 0.1% BASE	N62471 001 SEP 27, 1983
/AT/	/THAMES/	/EQ 1MG BASE/GM/	/N62427/001/ /MAY/26,/1983/
AT	THAMES	EQ 0.1% BASE	N62427 001 MAY 26, 1983

INJECTABLE; INJECTION
APOGEN

>_ADD_>	AP	KING PHARMS	EQ 10MG BASE/ML	N62289 001
>_ADD_>	AP		EQ 40MG BASE/ML	N62289 002
>_DLT_>/	AP/	/SMITHKLINE/BEECHAM/	/EQ 10MG BASE/ML/	/N62289/001/
>_DLT_>/	AP/		/EQ 40MG BASE/ML/	/N62289/002/

/ **GARAMYCIN** /

/AP//+/	/SCHERING/	/EQ 2MG BASE/ML/	/N50505/001/

GENTAMICIN SULFATE

INJECTABLE; INTRATHECAL
GARAMYCIN

+	SCHERING	EQ 2MG BASE/ML	N50505 001

OINTMENT; OPHTHALMIC
GARAMYCIN

/AT//+/	/SCHERING/	/EQ 3MG BASE/GM/	/N50425/001/
AT +	SCHERING	EQ 0.3% BASE	N50425 001

GENTACIDIN

/AT/	/IOLAB/	/EQ 3MG BASE/GM/	/N62501/001/ /JUL/26,/1984/
AT	IOLAB	EQ 0.3% BASE	N62501 001 JUL 26, 1984

OINTMENT; TOPICAL
GARAMYCIN

/AT//+/	/SCHERING/	/EQ 1MG BASE/GM/	/N60463/001/
AT +	SCHERING	EQ 0.1% BASE	N60463 001

GENTAFAIR

/AT/	/PHARMAFAIR/	/EQ 0.1% BASE/	/N62444/001/ /MAY/26,/1983/
	@ PHARMAFAIR	EQ 0.1% BASE	N62444 001 MAY 26, 1983

GENTAMICIN

/AT/	/CLAY/PARK/	/EQ 1MG BASE/GM/	/N62351/001/ /FEB/18,/1982/
AT	CLAY PARK	EQ 0.1% BASE	N62351 001 FEB 18, 1982

GENTAMICIN SULFATE

AT	BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001 APR 29, 1994
/AT/	/FOUGERA/	/EQ 1MG BASE/GM/	/N62533/001/ /OCT/05,/1984/
AT	FOUGERA	EQ 0.1% BASE	N62533 001 OCT 05, 1984
/AT/	/NMC/	/EQ 1MG BASE/GM/	/N62496/001/ /MAR/14,/1984/
AT	NMC	EQ 0.1% BASE	N62496 001 MAR 14, 1984
/AT/	/PHARMADERM/	/EQ 1MG BASE/GM/	/N62534/001/ /OCT/10,/1984/
AT	PHARMADERM	EQ 0.1% BASE	N62534 001 OCT 10, 1984
/AT/	/THAMES/	/EQ 1MG BASE/GM/	/N62477/001/ /DEC/23,/1983/
AT	THAMES	EQ 0.1% BASE	N62477 001 DEC 23, 1983

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

/AT//+//SCHERING/	/EQ 3MG BASE/ML/	/N50039/002/
AT + SCHERING	EQ 0.3% BASE	N50039 002

GENOPTIC

/AT/	/ALLERGAN/	/EQ 3MG BASE/ML/	/N62452/001/ /OCT/10,/1984/
AT	ALLERGAN	EQ 0.3% BASE	N62452 001 OCT 10, 1984

GENTACIDIN

/AT/	/IOLAB/	/EQ 3MG BASE/ML/	/N62480/001/ /MAR/30,/1984/
AT	IOLAB	EQ 0.3% BASE	N62480 001 MAR 30, 1984

GENTAFAIR

/AT/	/PHARMAFAIR/	/EQ 3MG BASE/ML/	/N62440/001/ /MAY/03,/1983/
AT	PHARMAFAIR	EQ 0.3% BASE	N62440 001 MAY 03, 1983

GENTAMICIN SULFATE

/AT/	/AKORN/	/EQ 3MG BASE/ML/	/N62635/001/ /JAN/08,/1987/
AT	AKORN	EQ 0.3% BASE	N62635 001 JAN 08, 1987
AT	BAUSCH AND LOMB	EQ 0.3% BASE	N64048 001 MAY 11, 1994
/AT/	/STERIS/	/EQ 3MG BASE/ML/	/N62523/001/ /NOV/25,/1985/
AT	STERIS	EQ 0.3% BASE	N62523 001 NOV 25, 1985

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	MYLAN	5MG	N74226 001 MAY 10, 1994
AB		10MG	N74226 002 MAY 10, 1994

GLUCOTROL

AB	PFIZER	5MG	N17783 001 MAY 08, 1984
AB +		10MG	N17783 002 MAY 08, 1984

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL

GLUCOTROL XL

+ PFIZER	5MG	N20329 001 APR 26, 1994
+	10MG	N20329 002 APR 26, 1994

GLUTETHIMIDE

TABLET; ORAL

GLUTETHIMIDE

/AA/	/HALSEY/	/250MG/	/N89458/001/ /OCT/10,/1986/
	HALSEY	250MG	N89458 001 OCT 10, 1986
/AA/	/LANNETT/	/250MG/	/N83475/001/
/AA/		/500MG/	/N85571/001/
	@ LANNETT	250MG	N83475 001
	@	500MG	N85571 001

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

/AP/	/FUJISAWA/	/0.2MG/ML/	/N88475/001/ /JUN/12,/1984/
	@ FUJISAWA	0.2MG/ML	N88475 001 JUN 12, 1984

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

/AP/	/FUJISAWA/	/5,000 UNITS/VIAL/	/N17067/001/
/AP/		/20,000 UNITS/VIAL/	/N17067/003/
	@ FUJISAWA	5,000 UNITS/VIAL	N17067 001
	@	20,000 UNITS/VIAL	N17067 003

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

/AT/	/PHARMAFAIR/	/0.025MG/ML;EQ 1.75MG BASE/ML;/ /10,000 UNITS/ML/	/N62383/001/ /AUG/31,/1982/

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
/**NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN**/
@ PHARMAFAIR — 0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML — N62383 001 — AUG 31, 1982

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

AB	COPLEY PHARM	**EQ 4MG BASE**	**N74267 001**	JUN 01, 1994
AB		**EQ 8MG BASE**	**N74267 002**	JUN 01, 1994
AB	WATSON LABS	**EQ 4MG BASE**	**N74025 001**	FEB 28, 1994
AB		**EQ 8MG BASE**	**N74025 002**	FEB 28, 1994

WYTENSIN

AB	WYETH AYERST	**EQ 4MG BASE**	**N18587 001**	SEP 07, 1982
AB +		**EQ 8MG BASE**	**N18587 002**	SEP 07, 1982

HEPARIN CALCIUM

INJECTABLE; INJECTION
CALCIPARINE

+ CHOAY	25,000 UNITS/ML	N18237 001	
/+//DUPONT/	/25,000/UNITS/ML/	/N18237/001/	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

/BP/	/DANBURY/PHARMA/	/25MG;15MG;0.1MG/	/N87556/001/	
@	DANBURY PHARMA	25MG;15MG;0.1MG	N87556 001	

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

/AB/	/ZENITH/	**/50MG/**	/N84658/001/	
@	ZENITH	50MG	N84658 001	

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDROCHLOROTHIAZIDE W/ RESERPINE

/BP/	/ROXANE/	/50MG;0.125MG/	/N84603/001/	
@	ROXANE	50MG;0.125MG	N84603 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
DYAZIDE

/AB//+/	/SMITHKLINE/BEECHAM/	**/25MG;50MG/**	/N16042/002/	
	SMITHKLINE BEECHAM	25MG;37.5MG	N16042 003	MAR 03, 1994
@		25MG;50MG	N16042 002	

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

/AB/	/GENEVA/PHARMS/	**/25MG;50MG/**	/N73191/001/	
+	GENEVA PHARMS	25MG;50MG	/JUL/31,/1991/	
			N73191 001	JUL 31, 1991

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

/AT/	/LEMMON/	**/1%/**	/N85191/001/	
@	LEMMON	1%	N85191 001	
>DLT >**/AT/**	/PHARMAFAIR/	**/1%/**	/N87838/001/	
>DLT > >ADD > >ADD >	@ PHARMAFAIR	1%	/JUL/28,/1982/	
			N87838 001	JUL 28, 1982

ENEMA; RECTAL
CORTENEMA

AT +	SOLVAY	**100MG/60ML**	**N16199 001**	

HYDROCORTISONE

AT	COPLEY	**100MG/60ML**	**N74171 001**	MAY 27, 1994

GEL; TOPICAL
/NUTRACORT/

/AT//+/	/GALDERMA/	**/1%/**	/N84698/001/	
@	GALDERMA	1%	N84698 001	

PENECORT

/AT/	/ALLERGAN/HERBERT/	**/1%/**	/N88215/001/	
+	ALLERGAN HERBERT	1%	/JUN/06,/1984/	
			N88215 001	JUN 06, 1984

HYDROCORTISONE

LOTION; TOPICAL
HYDROCORTISONE

/AT/	/CLAY/PARK/	/1%/		/N85663/001/
	@ CLAY PARK	1%		N85663 001

OINTMENT; TOPICAL
HYDROCORTISONE

/AT/	/CLAY/PARK/	/1%/		/N85028/001/
	@ CLAY PARK	1%		N85028 001

TABLET; ORAL
HYDROCORTISONE

/BP/	/DANBURY/PHARMA/	/20MG/		/N80355/001/
	@ DANBURY PHARMA	20MG		N80355 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
/NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML;/		
		/10,000 UNITS/ML/		/N62394/001/
				/SEP/29,/1982/
	@ PHARMAFAIR	1%;EQ 3.5MG BASE/ML;		
		10,000 UNITS/ML		N62394 001
				SEP 29, 1982

SUSPENSION; OTIC
/OTICAIR/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML;/		
		/10,000 UNITS/ML/		/N62399/001/
				/NOV/18,/1982/
	@ PHARMAFAIR	1%;EQ 3.5MG BASE/ML;		
		10,000 UNITS/ML		N62399 001
				NOV 18, 1982

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HYDROCORTISONE ACETATE

/AT/	/PARKE/DAVIS/	/1%/		/N89914/001/
				/JAN/03,/1989/
	@ PARKE DAVIS	1%		N89914 001
				JAN 03, 1989

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE

/BP/	/STERIS/	/50MG/ML/		/N85214/001/
	@ STERIS	50MG/ML		N85214 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID

/+//BROCADES/PHARMA/		/0.1%/		/N18514/001/
				/MAR/31,/1982/
+	YAMANOUCHI	0.1%		N18514 001
				MAR 31, 1982

OINTMENT; TOPICAL
LOCOID

/@/BROCADES/PHARMA/		/0.1%/		/N18652/001/
				/OCT/29,/1982/
@	YAMANOUCHI	0.1%		N18652 001
				OCT 29, 1982

SOLUTION; TOPICAL
LOCOID

/+//BROCADES/PHARMA/		/0.1%/		/N19116/001/
				/FEB/25,/1987/
+	YAMANOUCHI	0.1%		N19116 001
				FEB 25, 1987

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

/AP/	/ABBOTT/	/EQ 250MG BASE/VIAL/		/N89578/001/
				/APR/11,/1989/
/AP/		/EQ 500MG BASE/VIAL/		/N89579/001/
				/APR/11,/1989/
/AP/		/EQ 1GM BASE/VIAL/		/N89580/001/
				/APR/11,/1989/
	@ ABBOTT	EQ 250MG BASE/VIAL		N89578 001
				APR 11, 1989
	@	EQ 500MG BASE/VIAL		N89579 001
				APR 11, 1989
	@	EQ 1GM BASE/VIAL		N89580 001
				APR 11, 1989

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION
/DELALUTIN/

/AO//+//SQUIBB/	/125MG/ML/		/N10347/004/
/AO/	/125MG/ML/		/N16911/001/
/AO//+/	/250MG/ML/		/N10347/002/
/AO/	/250MG/ML/		/N16911/002/
@ SQUIBB	125MG/ML		N10347 004
@	125MG/ML		N16911 001
@	250MG/ML		N10347 002
@	250MG/ML		N16911 002

HYDROXYPROGESTERONE CAPROATE

/AO/ /STERIS/	/125MG/ML/		/N17439/001/
AO + STERIS	125MG/ML		N17439 001
/AO/	/250MG/ML/		/N17439/002/
+	250MG/ML		N17439 002

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

/AP/ /SMITH/NEPHEW/SOLOPAK/	/25MG/ML/		/N87591/001/
/AP/	/50MG/ML/		/N87593/001/
/AP/	/50MG/ML/		/N87595/001/
AP SOLOPAK	25MG/ML		N87591 001
AP	50MG/ML		N87593 001
AP	50MG/ML		N87595 001

/ORGATRAX/

/AP/ /ORGANON/	/25MG/ML/		/N87014/001/
/AP/	/50MG/ML/		/N87014/002/
@ ORGANON	25MG/ML		N87014 001
@	50MG/ML		N87014 002

TABLET; ORAL
HYDROXYZINE HCL

AB ROYCE	10MG		N81149 001
			MAR 18, 1994
AB	25MG		N81150 001
			MAR 18, 1994
AB	50MG		N81151 001
			MAR 18, 1994

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME

+ GENZYME	200 UNITS/VIAL		N20367 001
			MAY 23, 1994

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION
OCTREOSCAN

MALLINCKRODT	3MCI/ML		N20314 001
			JUN 02, 1994

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

/AB/ /CHELSEA/LABS/	/25MG/		/N18690/001/
			/JUL/31,/1984/
/AB/	/50MG/		/N18690/002/
			/JUL/31,/1984/
@ CHELSEA LABS	25MG		N18690 001
			JUL 31, 1984
@	50MG		N18690 002
			JUL 31, 1984

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN R

+ LILLY	500 UNITS/ML		N18780 004
			MAR 31, 1994

INVERT SUGAR

/INJECTABLE;/INJECTION/
/TRAVERT/10%/IN/PLASTIC/CONTAINER/

/BAXTER/	/10GM/100ML/		/N16717/001/
@ BAXTER	10GM/100ML		N16717 001

IOBENGUANE SULFATE I 131

INJECTABLE; INJECTION
IOBENGUANE SULFATE I 131

CIS	2.3MCI/ML		N20084 001
			MAR 25, 1994

IODOHIPPURATE SODIUM, I-123

/INJECTABLE;/INJECTION/
/NEPHROFLOW/

/MEDI/PHYSICS/	/1MCI/ML/		/N18289/001/
			/DEC/28,/1984/

IODOHIPPURATE SODIUM, I-123

/INJECTABLE;/INJECTION/		
/NEPHROFLOW/		
@ MEDI PHYSICS	1MCI/ML	N18289 001 DEC 28, 1984

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL		
RIFATER		
+ MARION MERRELL DOW	50MG;300MG;120MG	N50705 001 MAY 31, 1994

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION		
ISUPREL		
/+//STERLING/WINTHROP/	/0.113MG/INH/	/N11178/001/
+ STERLING WINTHROP	0.131MG/INH	N11178 001

ISRADIPINE

CAPSULE; ORAL		
DYNACIRC		
+ SANDOZ	5MG	N19546 002 DEC 20, 1990
	/5MG/	/N19546/002/ /DEC/20,/1990/
TABLET, EXTENDED RELEASE; ORAL		
DYNACIRC CR		
+ SANDOZ	5MG	N20336 001 JUN 01, 1994
+	10MG	N20336 002 JUN 01, 1994

KANAMYCIN SULFATE

CAPSULE; ORAL		
KANTREX		
/+//APOTHECON/	/EQ/500MG/BASE/	/N61911/001/
+ APOTHECON	EQ 500MG BASE	N62726 001 MAR 06, 1987
@	EQ 500MG BASE	N60516 001
@	EQ 500MG BASE	N61911 001
	/EQ/500MG/BASE/	/N62726/001/ /MAR/06,/1987/

KANAMYCIN SULFATE

CAPSULE; ORAL		
KANTREX		
/AB//+//BRISTOL/	/EQ 500MG BASE/	/N60516/001/
INJECTABLE; INJECTION		
KANTREX		
/AP//+//APOTHECON/	/EQ 75MG BASE/2ML/	/N61655/003/
/AP/	/EQ 75MG BASE/2ML/	/N61901/003/
AP + APOTHECON	EQ 75MG BASE/2ML	N61901 003
/AP//+/	/EQ 500MG BASE/2ML/	/N61655/001/
/AP/	/EQ 500MG BASE/2ML/	/N61901/001/
AP +	EQ 500MG BASE/2ML	N61901 001
/AP//+/	/EQ 1GM BASE/3ML/	/N61655/002/
/AP/	/EQ 1GM BASE/3ML/	/N61901/002/
AP +	EQ 1GM BASE/3ML	N61901 002
@	EQ 75MG BASE/2ML	N61655 003
@	EQ 75MG BASE/2ML	N62564 001 SEP 21, 1984
@	EQ 500MG BASE/2ML	N61655 001
@	EQ 500MG BASE/2ML	N62564 002 SEP 21, 1984
@	EQ 1GM BASE/3ML	N61655 002
@	EQ 1GM BASE/3ML	N62564 003 SEP 21, 1984
/AP/ /BRISTOL/	/EQ 75MG BASE/2ML/	/N62564/001/ /SEP/21,/1984/
/AP/	/EQ 500MG BASE/2ML/	/N62564/002/ /SEP/21,/1984/
/AP/	/EQ 1GM BASE/3ML/	/N62564/003/ /SEP/21,/1984/
KLEBCIL		
> ADD > @ KING PHARMS	EQ 75MG BASE/2ML	N62170 001
> ADD > @	EQ 500MG BASE/2ML	N62170 002
> ADD > @	EQ 1GM BASE/3ML	N62170 003
> DLT > /@/SMITHKLINE/BEECHAM/	/EQ/75MG/BASE/2ML/	/N62170/001/
> DLT > /@/	/EQ/500MG/BASE/2ML/	/N62170/002/
> DLT > /@/	/EQ/1GM/BASE/3ML/	/N62170/003/

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION		
LEUCOVORIN CALCIUM		
AP ELKINS SINN	EQ 100MG BASE/VIAL	N81224 001 JUN 03, 1994
/+//IMMUNEX/	/EQ/3MG/BASE/ML/	/N08107/001/
@ IMMUNEX	EQ 3MG BASE/ML	N08107 001

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAGAN			
AT	+ ALLERGAN	0.25%	N19814 001	
			JUN 28, 1989	
AT	+	0.5%	N19219 002	
			DEC 19, 1985	
	LEVOBUNOLOL HCL			
AT	BAUSCH AND LOMB	0.25%	N74307 001	
			MAR 04, 1994	
AT		0.5%	N74326 001	
			MAR 04, 1994	

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	/ARESTOCAINE HCL W/ LEVONORDEFRIN/		
/AP/	/CARLISLE/	/0.05MG/ML;2%/	/N85010/001/
	@ SOLVAY	0.05MG/ML;2%	N85010 001

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

	MYLOCAINE		
AT	PENNEX	4%	N87881 001
			NOV 18, 1982
	/@/	/4%/	/N87881/001/
			/NOV/18,/1982/
	PEDIATRIC LTA KIT		
/AT/	/ABBOTT/	/2%/	/N88572/001/
			/JUL/31,/1984/
	@ ABBOTT	2%	N88572 001
			JUL 31, 1984

LIOTRIX (T4;T3)

TABLET; ORAL

>_DLT_>	/EUTHROID-0.5/			
>_DLT_>	/PARKE/DAVIS/	/0.03MG;0.0075MG/	/N16680/001/	
>_ADD_>	@ PARKE DAVIS	0.03MG;0.0075MG	N16680 001	
>_DLT_>	/EUTHROID-1/			
>_DLT_>	/PARKE/DAVIS/	/0.06MG;0.015MG/	/N16680/002/	
>_ADD_>	@ PARKE DAVIS	0.06MG;0.015MG	N16680 002	
>_DLT_>	/EUTHROID-2/			
>_DLT_>	/PARKE/DAVIS/	/0.12MG;0.03MG/	/N16680/003/	
>_ADD_>	@ PARKE DAVIS	0.12MG;0.03MG	N16680 003	
>_DLT_>	/EUTHROID-3/			
>_DLT_>	/+//PARKE/DAVIS/	/0.18MG;0.045MG/	/N16680/004/	
>_ADD_>	@ PARKE DAVIS	0.18MG;0.045MG	N16680 004	

LISINOPRIL

TABLET; ORAL

	PRINIVIL			
AB	MERCK	2.5MG	N19558 006	
			JAN 28, 1994	
	ZESTRIL			
AB	ZENECA	2.5MG	N19777 005	
			APR 29, 1993	

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

	/LITHOBID/		
	/+//CIBA/	/300MG/	/N18027/001/
	@ CIBA	300MG	N18027 001

LORAZEPAM

INJECTABLE; INJECTION

	ATIVAN			
AP	+ WYETH AYERST	2MG/ML	N18140 001	
AP	+	4MG/ML	N18140 002	
	LORAZEPAM			
AP	ABBOTT	2MG/ML	N74280 001	
			MAY 27, 1994	
AP		2MG/ML	N74282 001	
			MAY 27, 1994	
AP		4MG/ML	N74280 002	
			MAY 27, 1994	
AP		4MG/ML	N74282 002	
			MAY 27, 1994	
AP	STERIS	2MG/ML	N74276 001	
			APR 15, 1994	
AP		4MG/ML	N74276 002	
			APR 15, 1994	
AP	STERLING WINTHROP	2MG/ML	N74243 001	
			APR 12, 1994	
AP		2MG/ML	N74300 001	
			APR 12, 1994	
AP		4MG/ML	N74243 002	
			APR 12, 1994	

LORAZEPAM

TABLET; ORAL
LORAZEPAM

/**AB**/	/WARNER/CHILCOTT/	/**1MG**/	/N71038/001/ /JAN/12,/1988/	
/**AB**/		/**2MG**/	/N71039/001/ /JAN/12,/1988/	
	@ WARNER CHILCOTT	1MG	N71038 001 JAN 12, 1988	
	@	2MG	N71039 001 JAN 12, 1988	

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER

ABBOTT	4GM/100ML	N20309 001	JUN 24, 1994
	80MG/ML	N20309 002	JUN 24, 1994

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
/**ARESTOCAINE HCL**/

/**AP**/	/CARLISLE/	/**3%**/	/N84777/002/ /APR/18,/1982/	
	@ SOLVAY	3%	N84777 002 APR 18, 1982	

MEPROBAMATE

TABLET; ORAL
/**MEPRIAM**/

/**AA**/	/LEMMON/	/**400MG**/	/N16069/001/	
	@ LEMMON	400MG	N16069 001	

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE

/**AP**/	/FUJISAWA/	/**EQ 10MG BASE/ML**/	/N80431/001/	
	@ FUJISAWA	EQ 10MG BASE/ML	N80431 001	

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE

AB	MIKART	**25MG**	**N40062 001** JAN 27, 1994
AB		**50MG**	**N40062 002** JAN 27, 1994

METHDILAZINE

>_DLT_>	/TABLET,/CHEWABLE;/ORAL/			
>_DLT_>	/TACARYL/			
>_DLT_>	/WESTWOOD/SQUIBB/	/3.6MG/		/N11950/009/
>_ADD_>	@ WESTWOOD SQUIBB	3.6MG		N11950 009

METHDILAZINE HYDROCHLORIDE

>_DLT_>	/SYRUP;/ORAL/			
>_DLT_>	/TACARYL/			
>_DLT_>	/WESTWOOD/SQUIBB/	/4MG/5ML/		/N11950/007/
>_ADD_>	@ WESTWOOD SQUIBB	4MG/5ML		N11950 007
>_DLT_>	/TABLET;/ORAL/			
>_DLT_>	/TACARYL/			
>_DLT_>	/WESTWOOD/SQUIBB/	/8MG/		/N11950/006/
>_ADD_>	@ WESTWOOD SQUIBB	8MG		N11950 006

METHOTREXATE SODIUM

INJECTABLE; INJECTION
FOLEX PFS

/**AP**/	/ADRIA/	/**EQ 25MG BASE/ML**/	/N89180/001/ /JAN/03,/1986/	
	@ ADRIA	EQ 25MG BASE/ML	N89180 001 JAN 03, 1986	

METHSCOPOLAMINE BROMIDE

TABLET; ORAL
PAMINE

>_ADD_> **AA**	BRADLEY	**2.5MG**		**N08848 001**
>_DLT_>/**AA**/	/UPJOHN/	/**2.5MG**/		/N08848/001/

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

/AP/	/ABBOTT/	/EQ 40MG BASE/VIAL/	/N89573/001/	
			/FEB/22,/1991/	
/AP/		/EQ 125MG BASE/VIAL/	/N89574/001/	
			/FEB/22,/1991/	
/AP/		/EQ 500MG BASE/VIAL/	/N89575/001/	
			/FEB/22,/1991/	
	@ ABBOTT	EQ 40MG BASE/VIAL	N89573 001	
			FEB 22, 1991	
	@	EQ 125MG BASE/VIAL	N89574 001	
			FEB 22, 1991	
	@	EQ 500MG BASE/VIAL	N89575 001	
			FEB 22, 1991	

/METHYLPREDNISOLONE/

/AP/	/ORGANON/	/EQ 500MG BASE/VIAL/	/N87535/001/	
			/JUN/25,/1982/	
/AP/		/EQ 1GM BASE/VIAL/	/N87535/002/	
			/JUN/25,/1982/	
	@ ORGANON	EQ 500MG BASE/VIAL	N87535 001	
			JUN 25, 1982	
	@	EQ 1GM BASE/VIAL	N87535 002	
			JUN 25, 1982	

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL

METHYLTESTOSTERONE

	/PRIVATE/FORM/	/5MG/	/N83836/001/
	@ PRIVATE FORM	5MG	N83836 001
/BP/	/TABLICAPS/	/10MG/	/N85125/001/
	@ TABLICAPS	10MG	N85125 001

TABLET; ORAL

METHYLTESTOSTERONE

/BP/	/PUREPAC/	/10MG/	/N80475/002/
/BP/		/25MG/	/N80475/003/
	@ PUREPAC	10MG	N80475 002
	@	25MG	N80475 003
/BP/	/TABLICAPS/	/10MG/	/N80313/001/
/BP/		/25MG/	/N85270/001/
	@ TABLICAPS	10MG	N80313 001
	@	25MG	N85270 001
/BP/	/WEST/WARD/	/10MG/	/N84331/001/
/BP/		/25MG/	/N84331/002/
	@ WEST WARD	10MG	N84331 001
	@	25MG	N84331 002

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

MAXOLON

>ADD>	**AB**	KING PHARMS	**EQ 10MG BASE**	**N70106 001**
>ADD>				MAR 04, 1986
>DLT>	**/AB/**	/SMITHKLINE/BEECHAM/	**/EQ 10MG BASE/**	/N70106/001/
>DLT>				/MAR/04,/1986/

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

AB	APOTHECON	**50MG**	**N74258 001**
			JAN 27, 1994
AB		**100MG**	**N74258 002**
			JAN 27, 1994
AB	COPLEY	**50MG**	**N74333 001**
			JAN 27, 1994
AB		**100MG**	**N74333 002**
			JAN 27, 1994
AB	GENEVA PHARMS	**50MG**	**N73288 001**
			MAR 25, 1994
AB		**100MG**	**N73289 001**
			MAR 25, 1994
>ADD> **AB**	PUREPAC PHARM	**50MG**	**N74380 001**
>ADD>			JUL 29, 1994
>ADD> **AB**		**100MG**	**N74380 002**
>ADD>			JUL 29, 1994
AB	WATSON LABS	**50MG**	**N74217 001**
			MAY 27, 1994
AB		**100MG**	**N74217 002**
			MAY 27, 1994

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

/MINOCIN/		
/@/LEDERLE/	/EQ/50MG/BASE/	/N50451/003/
		/AUG/10,/1982/
/@/	/EQ/100MG/BASE/	/N50451/002/
		/AUG/10,/1982/
MINOCYCLINE HCL		
LEDERLE	EQ 50MG BASE	N50451 003
		AUG 10, 1982
	EQ 100MG BASE	N50451 002
		AUG 10, 1982

NAFCILLIN SODIUM

INJECTABLE; INJECTION

	NAFCIL			
AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N61984 001**	
AP		**EQ 1GM BASE/VIAL**	**N61984 002**	
AP		**EQ 2GM BASE/VIAL**	**N61984 003**	
AP		**EQ 4GM BASE/VIAL**	**N61984 005**	
/**AP**/	/BRISTOL/	/**EQ 500MG BASE/VIAL**/	/N61984/001/	
/**AP**/		/**EQ 1GM BASE/VIAL**/	/N61984/002/	
/**AP**/		/**EQ 2GM BASE/VIAL**/	/N61984/003/	
/**AP**/		/**EQ 4GM BASE/VIAL**/	/N61984/005/	
	UNIPEN			
AP	WYETH AYERST	**EQ 10GM BASE/VIAL**	**N50320 005**	
	@	EQ 20GM BASE/VIAL	N50320 006	

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	/**NAFAZAIR**/			
/**AT**/	/PHARMAFAIR/	/**0.1%**/	/N88101/001/ /APR/15,/1983/	
	NAFAZAIR			
AT	BAUSCH AND LOMB	**0.1%**	**N40073 001** MAY 25, 1994	
	@ PHARMAFAIR	0.1%	N88101 001 APR 15, 1983	

NAPROXEN

SUSPENSION; ORAL

	NAPROSYN			
AB	+ SYNTEX	**25MG/ML**	**N18965 001** MAR 23, 1987	
	NAPROXEN			
AB	ROXANE	**25MG/ML**	**N74190 001** MAR 30, 1994	

TABLET; ORAL

	NAPROSYN			
/**AB**/	/SYNTEX/	/**500MG**/	/N17581/004/ /APR/15,/1982/	
AB	+ SYNTEX	**500MG**	**N17581 004** APR 15, 1982	

NAPROXEN

TABLET; ORAL

	NAPROXEN			
AB	ROXANE	**250MG**	**N74211 001** FEB 28, 1994	
AB		**375MG**	**N74211 002** FEB 28, 1994	
AB		**500MG**	**N74211 003** FEB 28, 1994	

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	COPLEY	**EQ 250MG BASE**	**N74289 001** JAN 27, 1994	
AB		**EQ 500MG BASE**	**N74289 002** JAN 27, 1994	

NEOMYCIN SULFATE

TABLET; ORAL

	NEOMYCIN SULFATE			
/**AA**/	/LANNETT/	/**EQ 350MG BASE**/	/N60607/001/	
	@ LANNETT	EQ 350MG BASE	N60607 001	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

	HABITROL			
/BC/	/BASEL/PHARMS/	/7MG/24HR/	/N20076/001/ /NOV/27,/1991/	
BC +	BASEL PHARMS	7MG/24HR	N20076 001 NOV 27, 1991	
/BC/		/14MG/24HR/	/N20076/002/ /NOV/27,/1991/	
BC +		14MG/24HR	N20076 002 NOV 27, 1991	
/BC/		/21MG/24HR/	/N20076/003/ /NOV/27,/1991/	
BC +		21MG/24HR	N20076 003 NOV 27, 1991	

NITROFURANTOIN

TABLET; ORAL
/FURALAN/

/AB/	/LANNETT/	/50MG/	/N80017/001/	
/AB/		/100MG/	/N80017/002/	
	@ LANNETT	50MG	N80017 001	
	@	100MG	N80017 002	

NITROFURAZONE

OINTMENT; TOPICAL
NITROFURAZONE

/AT/	/LANNETT/	/0.2%/	/N84393/001/	
	@ LANNETT	0.2%	N84393 001	

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

/AP/	/INTL/MEDICATION/	/5MG/ML/	/N70026/001/ /SEP/10,/1985/	
	@ INTL MEDICATION	5MG/ML	N70026 001 SEP 10, 1985	
	/NITRONAL/ /+//BOSKAMP/	/1MG/ML/	/N18672/001/ /AUG/30,/1983/	
	@ G POHL BOSKAMP	1MG/ML	N18672 001 AUG 30, 1983	

NITROSTAT

/AP/	/PARKE/DAVIS/	/5MG/ML/	/N70863/001/ /JAN/08,/1987/	
	@ PARKE DAVIS	5MG/ML	N70863 001 JAN 08, 1987	
		/10MG/ML/	/N70871/001/ /JAN/08,/1987/	
	@	10MG/ML	N70871 001 JAN 08, 1987	
		/10MG/ML/	/N70872/001/ /JAN/08,/1987/	
	@	10MG/ML	N70872 001 JAN 08, 1987	

NORETHINDRONE

TABLET; ORAL
/NORLUTIN/

/+//PARKE/DAVIS/		/5MG/	/N10895/002/	>_ADD_>
	@ PARKE DAVIS	5MG	N10895 002	>_ADD_>

NYSTATIN

SUSPENSION; ORAL
NYSTATIN

AA	BAUSCH AND LOMB	100,000 UNITS/ML	N64042 001 FEB 28, 1994	
/AA/	/PHARMAFAIR/	/100,000 UNITS/ML/	/N62541/001/ /JAN/16,/1985/	
	@ PHARMAFAIR	100,000 UNITS/ML	N62541 001 JAN 16, 1985	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYCOLOG-II

AT	+ APOTHECON	100,000 UNITS/GM;0.1%	N60576 002 MAY 01, 1985	
AT		100,000 UNITS/GM;0.1%	N62606 001 MAY 15, 1985	
/AT//+//SQUIBB/		/100,000 UNITS/GM;0.1%/	/N60576/002/ /MAY/01,/1985/	
/AT/		/100,000 UNITS/GM;0.1%/	/N62606/001/ /MAY/15,/1985/	

NYSTATIN AND TRIAMCINOLONE ACETONIDE

/AT/	/BARRE/	/100,000 UNITS/GM;0.1%/	/N63010/001/ /DEC/20,/1988/	
	@ BARRE	100,000 UNITS/GM;0.1%	N63010 001 DEC 20, 1988	
/B*/	/CLAY/PARK/	/100,000/UNITS/GM;0.1%/	/N62186/002/ /JUN/06,/1985/	
	@ CLAY PARK	100,000 UNITS/GM;0.1%	N62186 002 JUN 06, 1985	
/AT/	/PHARMAFAIR/	/100,000 UNITS/GM;0.1%/	/N62657/001/ /JUL/30,/1986/	
	@ PHARMAFAIR	100,000 UNITS/GM;0.1%	N62657 001 JUL 30, 1986	

OINTMENT; TOPICAL
NYSTATIN-TRIAMCINOLONE ACETONIDE

/AT/	/PHARMADERM/	/100,000 UNITS/GM;0.1%/	/N62603/001/ /OCT/09,/1985/	
	@ PHARMADERM	100,000 UNITS/GM;0.1%	N62603 001 OCT 09, 1985	

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC

	+ ASTRA MERCK	20MG	N19810 001 SEP 14, 1989	

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC

> DLT >	/+//MERCK/	/20MG/	/N19810/001/	
> DLT >			/SEP/14,/1989/	

ORPHENADRINE HYDROCHLORIDE

/TABLET;/ORAL/
/DISIPAL/

	/3M/	/50MG/	/N10653/001/
	@ 3M	50MG	N10653 001

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL

+	SMITHKLINE BEECHAM	EQ 30MG BASE	N20031 003
			DEC 29, 1992
		/EQ/30MG/BASE/	/N20031/003/
			/DEC/29,/1992/

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM

	@ APOTHECON	1,000,000 UNITS/VIAL	N60362 001
	@	5,000,000 UNITS/VIAL	N60362 003
	@	10,000,000 UNITS/VIAL	N60362 004
	@	20,000,000 UNITS/VIAL	N60362 002
/AP/	/SQUIBB/	**/1,000,000 UNITS/VIAL/**	/N60362/001/
/AP/		**/5,000,000 UNITS/VIAL/**	/N60362/003/
/AP/		**/10,000,000 UNITS/VIAL/**	/N60362/004/
/AP/		**/20,000,000 UNITS/VIAL/**	/N60362/002/

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTACARINAT

AP	RHONE POULENC RORER	**300MG/VIAL**	**N73447 001**
			APR 28, 1994

PENTOBARBITAL SODIUM

CAPSULE; ORAL
/PENTOBARBITAL SODIUM/

/AA/	/LANNETT/	**/50MG/**	/N85937/001/
/AA/		**/100MG/**	/N85915/001/
	@ LANNETT	50MG	N85937 001
	@	100MG	N85915 001

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

/AA/	/ZENITH/	**/35MG/**	/N85611/001/
	@ ZENITH	35MG	N85611 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

/AA/	/LANNETT/	**/30MG/**	/N87022/001/
			/FEB/03,/1983/
	@ LANNETT	30MG	N87022 001
			FEB 03, 1983

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC PLAIN

AA	PENNEX	**5MG/5ML;6.25MG/5ML**	**N88897 001**
			JAN 04, 1985
	/@/	/5MG/5ML;6.25MG/5ML/	/N88897/001/
			/JAN/04,/1985/

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
/DIPHENYLAN/SODIUM/

/BX/	/LANNETT/	/100MG/	/N80857/002/
		/30MG/	/N80857/001/
	@ LANNETT	30MG	N80857 001
	@	100MG	N80857 002

PHYTONADIONE

INJECTABLE; INJECTION
PHYTONADIONE

/BP/	/SMITHKLINE/BEECHAM/	/1MG/0.5ML/	/N84060/001/
/BP/		/10MG/ML/	/N84060/002/
	@ SMITHKLINE BEECHAM	1MG/0.5ML	N84060 001
	@	10MG/ML	N84060 002

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL
SALAGEN

+	MGI	5MG	N20237 001 MAR 22, 1994

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	MUTUAL PHARM	**5MG**	**N74063 001** JAN 27, 1994
AB		**10MG**	**N74063 002** JAN 27, 1994

PIPERAZINE CITRATE

SYRUP; ORAL
/VERMIDOL/

/**AA**/	/SOLVAY/	/**EQ 500MG BASE/5ML**/	/N80992/001/
	@ SOLVAY	EQ 500MG BASE/5ML	N80992 001

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	NOVOPHARM	**10MG**	**N73637 001** JAN 28, 1994
AB		**20MG**	**N73638 001** JAN 28, 1994

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

/**AP**/	/FUJISAWA/	/**2MEQ/ML**/	/N87885/001/ /FEB/03,/1983/
	@ FUJISAWA	2MEQ/ML	N87885 001 FEB 03, 1983

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

/BX/	/BUNDY/	/5MG/	/N83675/001/
	@ BUNDY	5MG	N83675 001
/BX/	/ICN/	/5MG/	/N80236/001/
	@ ICN	5MG	N80236 001
/BX/	/INWOOD/	/5MG/	/N80748/001/
	@ INWOOD	5MG	N80748 001
/BX/	/TABLICAPS/	/5MG/	/N85170/001/
	@ TABLICAPS	5MG	N85170 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
/PREDAIR FORTE/

/**AT**/	/PHARMAFAIR/	/**EQ 0.9% PHOSPHATE**/	/N88165/001/ /MAR/28,/1983/
	@ PHARMAFAIR	EQ 0.9% PHOSPHATE	N88165 001 MAR 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

>ADD>	**AT**	BAUSCH AND LOMB	**EQ 0.11% PHOSPHATE**	**N40065 001** JUL 29, 1994
>ADD>	**AT**		**EQ 0.9% PHOSPHATE**	**N40070 001** JUL 29, 1994

PREDNISONE

TABLET; ORAL
PREDNISONE

/BX/	/BUNDY/	/5MG/	/N83676/001/
	@ BUNDY	5MG	N83676 001
/BX/	/DANBURY/PHARMA/	/50MG/	/N86867/001/
	@ DANBURY PHARMA	50MG	N86867 001
	@ FERRANTE	2.5MG	N80563 001
	@ FERRANTE	5MG	N80563 002
/BX/	/ICN/	/5MG/	/N80237/001/
	@ ICN	5MG	N80237 001

PREDNISONE

TABLET; ORAL

	PREDNISONE		
/BX/	/INWOOD/	/1MG/	/N80328/001/
/BX/		/2.5MG/	/N80306/001/
	@ INWOOD	1MG	N80328 001
	@	2.5MG	N80306 001
/BX/	/MK/LABS/	/2.5MG/	/N80563/001/
/BX/		/5MG/	/N80563/002/
/BX/	/NYLOS/	/5MG/	/N85115/001/
	@ NYLOS	5MG	N85115 001
/BX/	/REXALL/	/5MG/	/N80232/001/
	@ REXALL	5MG	N80232 001
/BX/	/SPERTI/	/1MG/	/N80359/001/
/BX/		/2.5MG/	/N80359/002/
/BX/		/5MG/	/N80359/003/
	@ SPERTI	1MG	N80359 001
	@	2.5MG	N80359 002
	@	5MG	N80359 003
/BX/	/WHITE/TOWNE/PAULSEN/	/20MG/	/N84913/002/
	@ WHITE TOWNE PAULSEN	20MG	N84913 002
/BX/	/1ST/TX/	/5MG/	/N80371/001/
	@ 1ST TX	5MG	N80371 001

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETHAZINE PLAIN		
AA	PENNEX	**6.25MG/5ML**	**N87953 001**
			NOV 15, 1982
	/@/	/6.25MG/5ML/	/N87953/001/
			/NOV/15,/1982/

TABLET; ORAL

	PROMETHAZINE HCL		
/BP/	/TABLICAPS/	/12.5MG/	/N84080/001/
/BP/		/25MG/	/N84027/001/
	@ TABLICAPS	12.5MG	N84080 001
	@	25MG	N84027 001
	/REMSED/		
/BP/	/DUPONT/	/25MG/	/N83176/002/
	@ DUPONT	25MG	N83176 002

PROPANTHELINE BROMIDE

TABLET; ORAL

	PRO-BANTHINE		
AA	ROBERTS LABS	**7.5MG**	**N08732 003**
AA		**15MG**	**N08732 002**
/**AA**/	/SCS/	/**7.5MG**/	/N08732/003/
/**AA**/		/**15MG**/	/N08732/002/

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	/KAINAIR/		
/**AT**/	/PHARMAFAIR/	/**0.5%**/	/N88087/001/
			/JUN/07,/1983/
	@ PHARMAFAIR	0.5%	N88087 001
			JUN 07, 1983

PROPYLTHIOURACIL

TABLET; ORAL

	PROPYLTHIOURACIL		
/BD/	/LANNETT/	/50MG/	/N80016/001/
	@ LANNETT	50MG	N80016 001
/BD/	/TABLICAPS/	/50MG/	/N80840/001/
	@ TABLICAPS	50MG	N80840 001

PROTIRELIN

INJECTABLE; INJECTION

	/RELEFACT TRH/		
/**AP**/	/FERRING/LABS/	/**0.5MG/ML**/	/N18087/001/
	THYREL TRH		
AP	FERRING LABS	**0.5MG/ML**	**N18087 001**

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

	/ALLERFED/		
/**AA**/	/PRIVATE/FORM/	/**60MG;2.5MG**/	/N88860/001/
			/JAN/31,/1985/
	@ PRIVATE FORM	60MG;2.5MG	N88860 001
			JAN 31, 1985

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL
/PYRIDOSTIGMINE/BROMIDE/
/KALI/DUPHAR/ /30MG/ /N89572/001/
/NOV/27,/1990/
@ SOLVAY 30MG N89572 001
NOV 27, 1990

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX
AB + ROBINS AH **300MG** N12796 002
QUINIDINE SULFATE
AB COPLEY PHARM **300MG** N40045 001
JUN 30, 1994

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
ZANTAC 150
GLAXO EQ 150MG BASE N20095 001
MAR 08, 1994
ZANTAC 300
+ GLAXO EQ 300MG BASE N20095 002
MAR 08, 1994

GRANULE, EFFERVESCENT; ORAL
ZANTAC 150
+ GLAXO EQ 150MG BASE/PACKET N20251 002
MAR 31, 1994

TABLET, EFFERVESCENT; ORAL
ZANTAC 150
+ GLAXO EQ 150MG BASE N20251 001
MAR 31, 1994

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON
+ ORGANON 10MG/ML N20214 002
MAR 17, 1994
ZEMURON (P/F)
+ ORGANON 10MG/ML N20214 001
MAR 17, 1994

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION
SEREVENT
+ GLAXO EQ 0.021MG BASE/INH N20236 001
FEB 04, 1994

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
/AA/ /LANNETT/ /**50MG**/ /N85909/001/
/AA/ /**100MG**/ /N85903/001/
@ LANNETT 50MG N85909 001
@ 100MG N85903 001
SECONAL SODIUM
/AA/ /LILLY/ /**50MG**/ /N86101/001/
/OCT/03,/1983/
LILLY 50MG N86101 001
OCT 03, 1983

SILVER SULFADIAZINE

DRESSING; TOPICAL
SILDIMAC
/@/BIOPLASTY/ /1%/ /N19608/001/
/NOV/30,/1989/
@ ENQUAY 1% N19608 001
NOV 30, 1989

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
/AP/ /ABBOTT/ /**50MG/VIAL**/ /N18450/001/
@ ABBOTT 50MG/VIAL N18450 001

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
BERLEX 120MG N19865 005
APR 20, 1994

STAVUDINE

CAPSULE; ORAL

ZERIT			
+ BRISTOL MYERS SQUIBB	40MG	N20412 005	JUN 24, 1994
@	5MG	N20412 001	JUN 24, 1994
	15MG	N20412 002	JUN 24, 1994
	20MG	N20412 003	JUN 24, 1994
	30MG	N20412 004	JUN 24, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE			
/AP/ /PFIZER/	/EQ 1GM BASE/2ML/	/N60111/001/	
PFIZER	EQ 1GM BASE/2.5ML	N60111 001	

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

/SULFAIR FORTE/			
/AT/ /PHARMAFAIR/	/30%/	/N88385/001/	/OCT/13,/1983/
@ PHARMAFAIR	30%	N88385 001	OCT 13, 1983
/SULFAIR-15/			
/AT/ /PHARMAFAIR/	/15%/	/N88186/001/	/MAY/25,/1983/
@ PHARMAFAIR	15%	N88186 001	MAY 25, 1983

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE				
>ADD> **AB**	EON LABS	**500MG**	**N40091 001**	JUL 29, 1994
>ADD>				

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM			
/AP/ /FUJISAWA/	/80MG/ML;16MG/ML/	/N70223/001/	/DEC/29,/1987/
@ FUJISAWA	80MG/ML;16MG/ML	N70223 001	DEC 29, 1987

SUSPENSION; ORAL

/BACTRIM/			
/AB//+//ROCHE/	/200MG/5ML;40MG/5ML/	/N17560/001/	
@ ROCHE	200MG/5ML;40MG/5ML	N17560 001	
BACTRIM PEDIATRIC			
/AB/ /ROCHE/	/200MG/5ML;40MG/5ML/	/N17560/002/	
AB + ROCHE	**200MG/5ML;40MG/5ML**	**N17560 002**	
TRIMETH/SULFA			
/AB/ /BARRE/	/200MG/5ML;40MG/5ML/	/N72398/001/	/MAY/23,/1988/
@ BARRE	200MG/5ML;40MG/5ML	N72398 001	MAY 23, 1988

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM			
/AB/ /EON/LABS/	/400MG;80MG/	/N18598/003/	/MAY/19,/1982/
@ EON LABS	400MG;80MG	N18598 003	MAY 19, 1982
/UROPLUS DS/			
/AB/ /SHIONOGI/	/800MG;160MG/	/N71816/001/	/SEP/28,/1987/
@ SHIONOGI	800MG;160MG	N71816 001	SEP 28, 1987
/UROPLUS SS/			
/AB/ /SHIONOGI/	/400MG;80MG/	/N71815/001/	/SEP/28,/1987/
@ SHIONOGI	400MG;80MG	N71815 001	SEP 28, 1987

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE		
/+//PHARMACIA/	/250MG/5ML/	/N18605/001/
+ PHARMACIA	250MG/5ML	N86983 001
@	250MG/5ML	N18605 001
	/250MG/5ML/	/N86983/001/

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE

/AB/	/LANNETT/	/500MG/	/N80085/001/	
	@ LANNETT	500MG	N80085 001	

TACROLIMUS

CAPSULE; ORAL
PROGRAF

+	FUJISAWA	EQ 1MG BASE	N50708 001	APR 08, 1994
+		EQ 5MG BASE	N50708 002	APR 08, 1994

INJECTABLE; INJECTION
PROGRAF

+	FUJISAWA	EQ 5MG BASE/ML	N50709 001	APR 08, 1994

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX

+	ZENECA	EQ 20MG BASE	N17970 002	MAR 21, 1994

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
/OSTEOSCAN-HDP/

	/MALLINCKRODT/	/N/A/	/N18321/001/	
	TECHNESCAN HDP			
	MALLINGKRODT	N/A	N18321 001	

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE

	DUPONT	N/A	N19785 001	DEC 21, 1990
	/DUPONT/MERCK/	/N/A/	/N19785/001/	/DEC/21,/1990/

TETRACYCLINE

/SYRUP;/ORAL/
/ACHROMYCIN V/

/AB//+/	/LEDERLE/	/EQ 125MG HCL/5ML/	/N50263/002/

/SUMYCIN/

/AB/	/SQUIBB/	/EQ 125MG HCL/5ML/	/N60400/001/

/TETRACYCLINE/

/AB/	/BARRE/	/EQ 125MG HCL/5ML/	/N60633/001/
/AB/	/MK/LABS/	/EQ 125MG HCL/5ML/	/N60174/001/

/TETRACYCLINE HCL/

/AB/	/PUREPAC/	/EQ 125MG HCL/5ML/	/N60291/001/

/TETRACYN/

/AB/	/PFIPHARMECS/	/EQ 125MG HCL/5ML/	/N60095/001/

/TETRAMED/

/AB/	/ZENITH/	/EQ 125MG HCL/5ML/	/N61468/001/

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

/AB/	/ICN/	/500MG/	/N60471/002/
	@ ICN	500MG	N60471 002

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE

+	ON SITE	12.7MG/FIBER	N50653 001 MAR 25, 1994

SYRUP; ORAL
ACHROMYCIN V

AB	+ LEDERLE	125MG/5ML	N50263 002

SUMYCIN

AB	SQUIBB	125MG/5ML	N60400 001

TETRACYCLINE HCL

AB	BARRE	125MG/5ML	N60633 001
AB	MK LABS	125MG/5ML	N60174 001
AB	PUREPAC	125MG/5ML	N60291 001

TETRACYN

AB	PFIPHARMECS	125MG/5ML	N60095 001

TETRAMED

AB	ZENITH	125MG/5ML	N61468 001

TABLET; ORAL
/PANMYCIN/

>DLT>		/UPJOHN/	/500MG/	/N61705/002/
>DLT>/AB/		@ UPJOHN	250MG	N61705 001
>ADD>		@	500MG	N61705 002
>ADD>				

TETRACYCLINE HYDROCHLORIDE

TABLET; ORAL
SUMYCIN

>_DLT_>	/AB/	/+//APOTHECON/	/500MG/		/N61147/004/
>_ADD_>		+ APOTHECON	500MG		N61147 004

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
SLO-BID

AB		RHONE POULENC RORER	100MG	N87892 001 JAN 31, 1985
AB			125MG	N89540 001 MAY 10, 1989
AB			200MG	N87893 001 JAN 31, 1985
AB	+		300MG	N87894 001 JAN 31, 1985

THEOPHYLLINE

AB		INWOOD LABS	100MG	N40052 001 FEB 14, 1994
AB			125MG	N40052 002 FEB 14, 1994
AB			200MG	N40052 003 FEB 14, 1993
AB			300MG	N40052 004 FEB 14, 1994

ELIXIR; ORAL
/LANOPHYLLIN/

/AA/		/LANNETT/	/80MG/15ML/	/N84578/001/
		@ LANNETT	80MG/15ML	N84578 001

THEOPHYLLINE

/AA/		/BARRE/	/80MG/15ML/	/N89223/001/ /MAY/27,/1988/
		@ BARRE	80MG/15ML	N89223 001 MAY 27, 1988
		@ CENCI	80MG/15ML	N87679 001 APR 15, 1982
/AA/		/LIFE/LABS/	/80MG/15ML/	/N87679/001/ /APR/15,/1982/

INJECTABLE; INJECTION
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER	4MG/ML	N18649 007 JUL 26, 1982

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ABBOTT	4MG/ML	N19211 007 DEC 14, 1984

THEOPHYLLINE

INJECTABLE; INJECTION
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		MCGAW	4MG/ML	N19212 003 NOV 07, 1984

SYRUP; ORAL
/THEOPHYLLINE/

/AA/		/BARRE/	/80MG/15ML/	/N86001/001/
		@ BARRE	80MG/15ML	N86001 001

THYROGLOBULIN

TABLET; ORAL
PROLOID

>_DLT_>	/BP/+//PARKE/DAVIS/		/65MG/	/N02245/002/
>_DLT_>			/32MG/	/N02245/005/
>_ADD_>		@ PARKE DAVIS	32MG	N02245 005
>_ADD_>		@	65MG	N02245 002
>_DLT_>			/100MG/	/N02245/008/
>_ADD_>		@	100MG	N02245 008
>_DLT_>			/130MG/	/N02245/010/
>_ADD_>		@	130MG	N02245 010
>_DLT_>			/200MG/	/N02245/007/
>_ADD_>		@	200MG	N02245 007

THYROGLOBULIN

>_ADD_>		+ GLOBAL PHARMS	64.8MG	N80151 001
>_DLT_>	/BP/	/RICHLYN/	/64.8MG/	/N80151/001/

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

AT		STERIS	0.3%	N63176 001 MAY 25, 1994

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP		APOTHECON	EQ 10MG BASE/ML	N64021 001 MAY 31, 1994
AP			EQ 40MG BASE/ML	N64021 002 MAY 31, 1994
AP			EQ 40MG BASE/ML	N64026 001 MAY 31, 1994

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	ABBOTT	EQ 1.6MG BASE/ML	N63081 006 JUN 02, 1993	

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE

/BP/	/MYLAN/	/2MG/	/N84406/001/
@	MYLAN	2MG	N84406 001

TRIAMCINOLONE ACETONIDE

AEROSOL; TOPICAL
KENALOG

+	APOTHECON	0.147MG/GM	N12104 001
/+/	/WESTWOOD/SQUIBB/	/0.147MG/GM/	/N12104/001/

CREAM; TOPICAL
KENALOG

AT	+	APOTHECON	**0.025%**	**N11601 003**
AT	+		**0.1%**	**N11601 006**
AT	+		**0.5%**	**N83943 001**
/**AT**/	/+/	/WESTWOOD/SQUIBB/	/**0.025%**/	/N11601/003/
/**AT**/	/+/		/**0.1%**/	/N11601/006/
/**AT**/	/+/		/**0.5%**/	/N83943/001/

OINTMENT; TOPICAL
KENALOG

AT	+	APOTHECON	**0.025%**	**N11600 003**
AT	+		**0.1%**	**N11600 001**
AT	+		**0.5%**	**N83944 001**
/**AT**/	/+/	/WESTWOOD/SQUIBB/	/**0.025%**/	/N11600/003/
/**AT**/	/+/		/**0.1%**/	/N11600/001/
/**AT**/	/+/		/**0.5%**/	/N83944/001/

TRIAZOLAM

TABLET; ORAL
HALCION

AB		UPJOHN	**0.125MG**	**N17892 003** APR 26, 1985
AB			**0.25MG**	**N17892 001** NOV 15, 1982

TRIAZOLAM

TABLET; ORAL
TRIAZOLAM

AB		ALPHAPHARM	**0.125MG**	**N74031 001** MAR 25, 1994
AB			**0.25MG**	**N74031 002** MAR 25, 1994
AB		ROXANE	**0.125MG**	**N74224 001** JUN 01, 1994
AB			**0.25MG**	**N74224 002** JUN 01, 1994

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL
/LANTRISUL/

/AB/		/LANNETT/	**/500MG/5ML/**	/N80123/002/
@		LANNETT	167MG/5ML;167MG/5ML;167	N80123 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
/MYDRIAFAIR/

>DLT>					
>DLT>	**/AT/**	/PHARMAFAIR/	**/0.5%/**		/N88274/001/
>DLT>					/SEP/16,/1983/
	/AT/	/PHARMAFAIR/	**/1%/**		/N88230/001/
					/SEP/16,/1983/
>ADD>		@ PHARMAFAIR	0.5%		N88274 001 SEP 16, 1983
>ADD>		@	1%		N88230 001 SEP 16, 1983

TROPICAMIDE

>ADD>	**AT**	BAUSCH AND LOMB	**0.5%**	**N40067 001** JUL 27, 1994
>ADD>				
>ADD>	**AT**		**1%**	**N40064 001** JUL 27, 1994
>ADD>				

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ISOPTIN SR

AB	+	KNOLL PHARM	**180MG**	**N19152 002** DEC 15, 1989

VERAPAMIL HCL

AB		BAKER NORTON	**180MG**	**N74330 001** JAN 31, 1994

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

/AP/	/BULL/	/10MG/VIAL/	/N89565/001/ /AUG/18,/1987/
AP	FAULDING	10MG/VIAL	N89565 001 AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

/AP/	/FUJISAWA/	/1MG/ML/	/N70411/001/ /SEP/10,/1986/
	@ FUJISAWA	1MG/ML	N70411 001 SEP 10, 1986

VINCRISTINE SULFATE PFS

/AP/	/BULL/	/1MG/ML/	/N71484/001/ /APR/19,/1988/
AP	FAULDING	1MG/ML	N71484 001 APR 19, 1988

ACETAMINOPHEN

SUPPOSITORY; RECTAL
INFANTS' FEVERALL
UPSHER SMITH 80MG N18337 004
AUG 26, 1992

TABLET, EXTENDED RELEASE; ORAL
TYLENOL
+ MCNEIL 650MG N19872 001
JUN 08, 1994

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MYCELEX-7 COMBINATION PACK
MILES 1%;100MG N20389 002
JUN 23, 1994

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
/BARRE/ /12.5MG/5ML/ /N70497/001/
/APR/25,/1989/
@ BARRE 12.5MG/5ML N70497 001
APR 25, 1989

IBUPROFEN

TABLET; ORAL
IBUPROFEN
MCNEIL 200MG N73019 001
MAR 30, 1994
PRIVATE FORM 200MG N73691 001
FEB 25, 1994

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
/HUMULIN/BR/
/+//LILLY/ /100/UNITS/ML/ /N19529/001/
/APR/28,/1986/
@ LILLY 100 UNITS/ML N19529 001
APR 28, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION
NPH INSULIN
/+//NOVO/NORDISK/ /40/UNITS/ML/ /N17929/001/
@ NOVO NORDISK 40 UNITS/ML N17929 001

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
NAPHCON-A
+ ALCON 0.025%;0.3% N20226 001
JUN 08, 1994

OPCON-A
+ BAUSCH AND LOMB 0.027%;0.315% N20065 001
JUN 08, 1994

NAPROXEN SODIUM

TABLET; ORAL
ALEVE
HAMILTON PHARMS EQ 200MG BASE N20204 002
JAN 11, 1994

PERMETHRIN

LOTION; TOPICAL
NIX
/+//BURROUGHS/WELLCOME/ /1%/ /N19918/001/
/MAY/02,/1990/
+ WARNER WELLCOME 1% N19918 001
MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC/24
+ CIBA 240MG N20021 002
DEC 15, 1992

/PSEUDOEPHEDRINE/HCL/
/ALZA/ /240MG/ /N20021/002/
/DEC/15,/1992/

SUDAFED 12 HOUR
/+//BURROUGHS/WELLCOME/ /120MG/ /N73585/001/
/OCT/31,/1991/
+ WARNER WELLCOME 120MG N73585 001
OCT 31, 1991

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 7 / JULY '94

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
BAXTER HLTHCARE N940404
JUL 28, 1994

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS

[January-July, 1994]

NAME *Generic/Chemical* *TN=Trade Name*	***INDICATION DESIGNATED***	***SPONSOR & ADDRESS*** *DD=Date Designated* *MA=Marketing Approval*
8-METHOXSALEN TN= UVADEX	FOR THE PREVENTION OF ACUTE REJECTION OF CARDIAC ALLOGRAFTS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 05/12/94 MA / /
AMINOSALICYLIC ACID TN= PASER GRANULES	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY 37 CLEVELAND LANE PRINCETON NJ 08540 DD 02/19/92 MA 06/30/94
AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA / /
AMMONIUM TETRATHIOMOLYBDATE TN=	TREATMENT OF WILSON'S DISEASE.	BREWER, GEORGE J. M.D. UNIVERSITY OF MICHIGAN MEDICAL SCHOOL ANN ARBOR MI 48109-0618 DD 01/31/94 MA / /
ANTIVENIN, POLYVALENT CROTALID (OVINE) FAB TN= CROTAB	TREATMENT OF ENVENOMATIONS INFLICTED BY NORTH AMERICAN CROTALID SNAKES.	THERAPEUTIC ANTIBODIES INC. 1500 21ST AVENUE SOUTH, SUITE 310 NASHVILLE TN 37212 DD 01/12/94 MA / /
ARGININE BUTYRATE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS, INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
AUTOLYMPHOCYTE THERAPY TN=	TREATMENT OF RENAL CELL CARCINOMA.	CELLCOR INCORPORATED 200 WELLS AVENUE NEWTON MA 02159 DD 07/12/94 MA / /
BETAINE TN=	TREATMENT OF HOMOCYSTINURIA.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 05/16/94 MA / /
BOVINE IMMUNOGLOBULIN CONCENTRATE, CRYPTOSPORIDIUM PARVUM TN= SPORIDIN-G	TREATMENT AND SYMPTOMATIC RELIEF OF CRYPTOSPORIDIUM PARVUM INFECTION OF THE GASTROINTESTINAL TRACT IN IMMUNOCOMPROMISED PATIENTS.	GALAGEN, INCORPORATED 4001 LEXINGTON AVENUE NORTH ARDEN HILLS MN 55126-2998 DD 03/01/94 MA / /
BUPRENORPHINE HYDROCHLORIDE TN=	TREATMENT OF OPIATE ADDICTION IN OPIATE USERS.	RECKITT & COLMAN PHARMACEUTICALS, INC. 1901 HUGUENOT ROAD RICHMOND VA 23235 DD 06/15/94 MA / /
BUSULFAN TN=	FOR USE AS PREPARATIVE THERAPY FOR MALIGNANCIES TREATED WITH BONE MARROW TRANSPLANTATION.	SPARTA PHARMACEUTICALS P.O. BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 04/21/94 MA / /
BUSULFAN TN=	AS PREPARATIVE THERAPY IN THE TREATMENT OF MALIGNANCIES WITH BONE MARROW TRANSPLANTATION.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 07/28/94 MA / /
CCD 1042 TN=	TREATMENT OF INFANTILE SPASMS.	COCENSYS, INC. 213 TECHNOLOGY DRIVE IRVINE CA 92718 DD 05/25/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD= Date Designated MA= Marketing Approval
CHIMERIC (MURINE VARIABLE, HUMAN CONSTANT) MAB TO CD20 TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 06/13/94 MA / /
CHOLINE CHLORIDE TN=	TREATMENT OF CHOLINE DEFICIENCY,SPECIFICALLY THE CHOLINE DEFICIENCY, HEPATIC STEATOSIS, AND CHOLESTASIS, ASSOCIATED WITH LONG-TERM PARENTERAL NUTRITION.	BUCHMAN, ALAN M.D. 6550 FANNIN, SUITE 1122 HOUSTON TX 77030 DD 02/10/94 MA / /
CLADRIBINE TN= LEUSTATIN	TREATMENT OF THE CHRONIC PROGRESSIVE FORM OF MULTIPLE SCLEROSIS.	BEUTLER, ERNEST M.D. 10666 NORTH TORREY PINES ROAD LA JOLLA CA 92037 DD 04/19/94 MA / /
CY-1899 TN=	TREATMENT OF CHRONIC ACTIVE HEPATITIS B INFECTION IN HLA-A2 POSITIVE PATIENTS.	CYTEL CORPORATION 3525 JOHN HOPKINS COURT SAN DIEGO CA 92121 DD 03/16/94 MA / /
DEHYDROEPIANDROSTERONE TN=	TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND THE REDUCTION IN THE USE OF STERIODS IN STEROID-DEPENDENT SLE PATIENTS.	GENELABS TECHNOLOGIES, INC. 505 PENOBSCOT DRIVE REDWOOD CITY CA 94063 DD 07/13/94 MA / /
DESMOPRESSIN ACETATE TN=	TREATMENT OF MILD HEMOPHILIA A AND VON WILLEBRAND'S DISEASE.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD COLLEGEVILLE PA 19426 DD 01/22/91 MA 03/07/94
FGN-1 TN=	FOR THE SUPPRESSION AND CONTROL OF COLONIC ADENOMATOUS POLYPS IN THE INHERITED DISEASE ADENOMATOUS POLYPOSIS COLI.	CELL PATHWAYS, INC. 1700 BROADWAY, SUITE 2000 DENVER CO 80290 DD 02/14/94 MA / /
GAMMALINOLENIC ACID TN=	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	ZURIER, ROBERT B. M.D. 55 LAKE AVE. UNIV. OF MASS. MED. CTR. WORCESTER MA 01655 DD 07/27/94 MA / /
HEME ARGINATE TN= NORMOSANG	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	LEIRAS, INCORPORATED 1850 CENTENNIAL PARK DRIVE, SUITE 450 RESTON VA 22091 DD 03/01/94 MA / /
I-131 RADIOLABELED B1 MONOCLONAL ANTIBODY TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	COULTER CORPORATION 11800 S.W. 147 AVENUE, P.O. BOX 169015 MIAMI FL 33116-9015 DD 05/16/94 MA / /
IMIGLUCERASE TN= CEREZYME	FOR REPLACEMENT THERAPY IN PATIENTS WITH TYPES I, II, AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139 DD 11/05/91 MA 05/23/94
ISOBUTYRAMIDE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INCORPORATED 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
L-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID TN= PROCYSTEINE	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	FREE RADICAL SCIENCES, INC. 245 FIRST STREET CAMBRIDGE MA 02142 DD 06/14/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD= Date Designated MA= Marketing Approval
L-CYSTEINE TN=	FOR THE PREVENTION AND LESSENING OF PHOTOSENSITIVITY IN ERYTHROPOIETIC PROTOPORPHYRIA.	TYSON AND ASSOCIATES 12832 SOUTH CHADRON AVENUE HAWTHORNE CA 90250 DD 05/16/94 MA / /
LIPOSOME ENCAPSULATED RECOMBINANT INTERLEUKIN-2 TN=	TREATMENT OF CANCERS OF THE KIDNEY AND RENAL PELVIS.	ONCOTHERAPEUTICS, INC. 1002 EASTPARK BOULEVARD CRANBURY NJ 08512 DD 06/20/94 MA / /
MITOGUAZONE TN=	TREATMENT OF DIFFUSE NON-HODGKIN'S LYMPHOMA, INCLUDING AIDS-RELATED DIFFUSE NON-HODGKIN'S LYMPHOMA.	CTRC RESEARCH FOUNDATION 11812 BECKET STREET POTOMAC MD 20854 DD 03/18/94 MA / /
N-TRIFLUOROACETYLADRIAMYCIN-14-V ALERATE TN=	TREATMENT OF CARCINOMA IN SITU OF THE URINARY BLADDER.	ANTHRA PHARMACEUTICALS, INC. 19 CARSON ROAD PRINCETON NJ 08540 DD 05/23/94 MA / /
OXANDROLONE TN= HEPANDRIN	TREATMENT OF MODERATE/SEVERE ACUTE ALCOHOLIC HEPATITIS IN THE PRESENCE OF MODERATE PROTEIN CALORIE MALNUTRITION.	BIO-TECHNOLOGY GENERAL CORPORATION 70 WOOD AVENUE SOUTH ISELIN NJ 08830 DD 03/18/94 MA / /
PEGASPARGASE TN= ONCASPAR	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL).	ENZON, INC. 40 KINGSBRIDGE ROAD PISCATAWAY NJ 08854-3998 DD 10/20/89 MA 02/01/94
PILOCARPINE TN= SALAGEN	TREATMENT OF XEROSTOMIA INDUCED BY RADIATION THERAPY FOR HEAD AND NECK CANCER.	MGI PHARMA, INC. SUITE 300 E, 9900 BREN ROAD EAST MINNEAPOLIS MN 55343-9667 DD 09/24/90 MA 03/22/94
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF THE RESPIRATORY SYMPTOMS OF CYSTIC FIBROSIS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02124 DD 01/12/94 MA / /
REDUCED L-GLUTATHIONE TN= CACHEXON	TREATMENT OF AIDS-ASSOCIATED CACHEXIA.	TELLURIDE PHARMACEUTICAL CORPORATION 146 FLANDERS DRIVE HILLSBOROUGH NJ 08876-4656 DD 02/14/94 MA / /
RIFAMPIN, ISONIAZID, PYRAZINAMIDE TN= RIFATER	SHORT-COURSE TREATMENT OF TUBERCULOSIS.	MARION MERRELL DOW, INC. P.O. BOX 9627 KANSAS CITY MO 64134-0627 DD 09/12/85 MA 05/31/94
SULFADIAZINE TN=	FOR USE IN COMBINATION WITH PYRIMETHAMINE FOR THE TREATMENT OF TOXOPLASMA GONDII ENCEPHALITIS IN PATIENTS WITH AND WITHOUT ACQUIRED IMMUNODEFICIENCY SYNDROME.	EON LABS MANUFACTURING, INC. 227-15 NORTH CONDUIT AVENUE LAURELTON NY 11413 DD 03/14/94 MA / /
TIZANIDINE HCL TN= ZANAFLEX	TREATMENT OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS AND SPINAL CORD INJURY.	ATHENA NEUROSCIENCES, INC. 800F GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 01/31/94 MA / /
TREOSULFAN TN= OVASTAT	TREATMENT OF OVARIAN CANCER.	MEDAC GmbH c/o PRINCETON REG. ASSOC. 65 SOUTH MAIN STREET PENNINGTION NJ 08534 DD 05/16/94 MA / /

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 1994 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ALBUTEROL (METERED DOSE INHALER - *IN VIVO*)	JAN 27, 1994	
FLURBIPROFEN (TABLET)	DEC 24, 1992	FEB 04, 1994
PHENYTOIN (SUSPENSION AND CHEWABLE TABLET)	MAR 04, 1994	
PHENYTOIN SODIUM (CAPSULE, EXTENDED AND PROMPT)	MAR 04, 1994	

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACYCLOVIR TABLET; ORAL	200MG	93 P-0339/ CP1	NOVOPHARM	NEW DOSAGE FORM	APPROVED FEB 08, 1994
ACYCLOVIR SODIUM INJECTABLE; INJECTION	25MG/ML (20ML/VIAL) (40ML/VIAL)	93 P-0469/ CP1	FAULDING	NEW DOSAGE FORM	APPROVED JUN 09, 1994
ESTRADIOL TABLET; ORAL	1.5MG	93 P-0344/ CP1	BRISTOL MYERS SQIBB	NEW STRENGTH	APPROVED JUN 08, 1994
LOPERAMIDE HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	1MG	93 P-0332/ CP1	ELLIS PHARM CONSULTING	NEW DOSAGE FORM	APPROVED FEB 08, 1994
METHYLTESTOSTERONE CAPSULE; ORAL	25MG	93 P-0459/ CP1	ICN	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	15MG 60MG 100MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	90MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUN 08, 1994
PREDNISONE TABLET, CHEWABLE; ORAL	1MG 2.5MG 20MG 50MG	93 P-0333/ CP1	DURA	NEW DOSAGE FORM	APPROVED JUN 08, 1994
PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE CAPSULE, EXTENDED RELEASE; ORAL	120MG 60MG	93 P-0367/ CP1	EURAND AMERICA	NEW DOSAGE FORM	APPROVED FEB 08, 1994

ERRATA

CIMETIDINE TABLET, EFFERVESCENT; ORAL	200MG 300MG 400MG 800MG	93 P-0048/ CP1*	FLEMINGTON PHARM	NEW DOSAGE FORM	APPROVED SEP 18, 1993

*Not previously published

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS

REFERENCES
NEW INDICATION

I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION

REFERENCES
PATENT USE CODE

U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19872 001	ACETAMINOPHEN; TYLENOL				NDF	JUN 08, 1997
	19806 001	ACRIVASTINE; SEMPREX-D	4650807	MAR 17, 2004	U-93		
			4501893	FEB 26, 2002		NC	MAR 25, 1997
>ADD>	74346 001	AMINOSALICYLIC ACID; PASER				ODE	JUN 30, 2001
	18700 001	AMRINONE LACTATE; INOCOR	4072746	JUL 31, 1998	U-7	NCE	JUL 31, 1994
	20304 001	APROTININ BOVINE; TRASYLOL				ODE	DEC 29, 2000
>ADD>	18831 001	ATRACURIUM BESYLATE; TRACRIUM	4179507	DEC 18, 1996		I-108	JUN 06, 1997
	20233 001	BUDESONIDE; RHINOCORT				NCE	FEB 14, 1999
>ADD>	18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
>DLT>	~~18731 001~~	~~BUSPIRONE HYDROCHLORIDE; BUSPAR~~	~~5015646~~	~~MAR 14, 2008~~	~~U-13~~		
>ADD>	18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
>DLT>	~~18731 002~~	~~BUSPIRONE HYDROCHLORIDE; BUSPAR~~	~~5015646~~	~~MAR 14, 2008~~	~~U-13~~		
	18343 001	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 002	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 003	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 005	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 006	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-101	JAN 28, 1997
						I-95	SEP 23, 1996
	20355 001	DESMOPRESSIN ACETATE; DESMOPRESSIN ACETATE				NP	MAR 07, 1997
						ODE	MAR 07, 2001
	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
>ADD>	20126 001	DOXEPIN HYDROCHLORIDE; ZONALON	4395420	JUL 26, 2000	U-95	NDF	APR 01, 1997
>ADD>	18922 004	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45	NCE	JAN 31, 1996
	20363 002	FAMCICLOVIR; FAMVIR				NCE	JUN 29, 1999
	20249 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19304 001	FENOFIBRATE; LIPIDIL	4058552	NOV 15, 1994		NCE	DEC 31, 1998
	19949 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19949 002	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19949 003	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19950 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	20322 001	FLUCONAZOLE; DIFLUCAN	4552884	NOV 12, 2002		I-100	DEC 30, 1996
			4302460	NOV 24, 1998		NCE	JAN 29, 1995
						NS	JUN 30, 1997
						I-107	JUN 30, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4018895	APR 19, 1994	U-12	I-102	FEB 28, 1997
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
	20235 001	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20235 002	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20235 003	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20329 001	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
	20329 002	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
	19778 003	HYDROCHLOROTHIAZIDE; PRINZIDE 10-12.5	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3	NS	NOV 18, 1996
	19888 001	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-12.5	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3		
	19888 002	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-25	4374829	DEC 30, 2001	U-3		
	19888 003	HYDROCHLOROTHIAZIDE; ZESTORETIC 10-12.5	4472380	SEP 18, 2001		NS	NOV 18, 1996
			4374829	DEC 30, 2001	U-3		
	20367 001	IMIGLUCERASE; CEREZYME				NCE	MAY 23, 1999
						ODE	MAY 23, 2001
	20314 001	INDIUM IN-111 PENTETREOTIDE KIT; OCTREOSCAN				NCE	JUN 02, 1999
	20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131				NCE	MAR 25, 1999
	50705 001	ISONIAZID; RIFATER				ODE	MAY 31, 2001
>ADD>	20336 001	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008		NDF	JUN 01, 1997
>ADD>			4950486	AUG 21, 2007		NCE	DEC 20, 1995
>ADD>			4946687	AUG 07, 2007			
>ADD>			4816263	MAR 28, 2006	U-3		
>ADD>			4783337	SEP 16, 2003	U-3		
>ADD>			4466972	AUG 21, 2003	U-3		
>ADD>	20336 002	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008		NDF	JUN 01, 1997
>ADD>			4950486	AUG 21, 2007		NCE	DEC 20, 1995
>ADD>			4946687	AUG 07, 2007			
>ADD>			4816263	MAR 28, 2006	U-3		
>ADD>			4783337	SEP 16, 2003	U-3		
>ADD>			4466972	AUG 21, 2003	U-3		
	20083 001	ITRACONAZOLE; SPORANOX				I-104	MAR 29, 1997
	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	JAN 18, 2000		NCE	NOV 10, 1998
	19558 006	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	20264 001	MEGESTROL ACETATE; MEGACE				NDF	SEP 10, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20065 001	NAPHAZOLINE HYDROCHLORIDE; OPCON-A				NC	JUN 08, 1997
>ADD>	20226 001	NAPHAZOLINE HYDROCHLORIDE; NAPHCON-A				NC	JUN 08, 1997
	19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 004	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 005	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	20262 001	PACLITAXEL; TAXOL				I-105	APR 13, 1997
>ADD>						D-24	JUN 22, 1997
	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
	20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20237 001	PILOCARPINE HYDROCHLORIDE; SALAGEN				ODE	MAR 22, 2001
						NDF	MAR 22, 1997
	20279 001	PREDNICARBATE; DERMATOP				NDF	OCT 29, 1996
	19627 001	PROPOFOL; DIPRIVAN				I-99	OCT 26, 1996
	20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAY 05, 2004			
			4576604	MAR 18, 2003			
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4128658	DEC 05, 1995		D-21	FEB 28, 1997
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4128658	DEC 05, 1995		D-21	FEB 28, 1997
	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4521431	JUN 04, 2002		D-21	FEB 28, 1997
	20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	JUL 02, 2008			
			4521431	JUN 04, 2002		I-75	MAY 19, 1995
			4128658	DEC 05, 1995		D-21	FEB 28, 1997
	20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	JUL 02, 2008			
			4521431	JUN 04, 2002		I-75	MAY 19, 1995
			4128658	DEC 05, 1995		D-21	FEB 28, 1997
	20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
			4521431	JUN 04, 2002		I-75	MAY 19, 1995
			4128658	DEC 05, 1995		D-21	FEB 28, 1997
	20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
			4521431	JUN 04, 2002		I-75	MAY 19, 1995
			4128658	DEC 05, 1995		D-21	FEB 28, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20236 001	SALMETEROL XINAFOATE; SEREVENT	4992474	FEB 12, 2008		NCE	FEB 04, 1999
19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19865 005	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
					ODE	OCT 30, 1999
20412 001	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 002	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 003	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 004	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 005	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
17376 001	SULFAMETHOXAZOLE; SEPTRA	4209513	JUN 24, 1997		I-103	JAN 07, 1997
17376 002	SULFAMETHOXAZOLE; SEPTRA DS	4209513	JUN 24, 1997		I-103	JAN 07, 1997
17377 001	SULFAMETHOXAZOLE; BACTRIM				I-103	JAN 07, 1997
17377 002	SULFAMETHOXAZOLE; BACTRIM DS				I-103	JAN 07, 1997
17560 002	SULFAMETHOXAZOLE; BACTRIM PEDIATRIC				I-103	JAN 07, 1997
17598 001	SULFAMETHOXAZOLE; SEPTRA				I-103	JAN 07, 1997
17598 002	SULFAMETHOXAZOLE; SEPTRA GRAPE				I-103	JAN 07, 1997
17970 002	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002			
19762 001	TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		4704282	NOV 03, 2004		NDF	OCT 12, 1996
19762 002	TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		4704282	NOV 03, 2004		NDF	OCT 12, 1996
20330 001	TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
		4195085	MAR 25, 1997		NP	NOV 04, 1996
20330 002	TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
		4195085	MAR 25, 1997		NP	NOV 04, 1996
20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	SEP 15, 2004	U-91	ODE	DEC 17, 2000